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Abstract 
 
 
 
Aim: To investigates the molecular changes that occur in response to VEGFr TKI therapy 
to better understand the acquired resistance process. A further goal is to investigate the 
potential of SRC inhibitors to slow or prevent VEGFr TKI resistance. 
Methods: Work was conducted in in vitro assays (MTS assays, scratch and transwell 
migration assays), a preclinical in vivo model of resistance (786-O xenografts) and IHC 
was conducted in sequential RCC patient tissue taken before and after 12-16 weeks of 
VEGFr TKI therapy.  
Findings:  100% (n=15) of 786-O xenografts developed a resistant phenotype when 
continually exposed to VEGFr-TKI treatment. PCR with species-specific probes showed 
VEGFr-TKI induced significant up-regulation of several pro-angiogenic factors in both the 
tumour and host compartments. These factors included VEGF ligand, FGF-2, HGF, and 
MET receptor. In addition, genes associated with epithelial mesenchymal transition were 
up-regulated in treated xenografts. Interestingly, the pro-angiogenic factor PGF and the 
pro-metastatic gene s100a4 were up-regulated with time, independently of treatment. 
Gene pathway analysis suggested VEGFr-TKI treatment induced a process resembling 
fibrosis or wound healing. Furthermore, collagen was increased in treated xenografts.  
IHC in RCC patient tissue verified that some of the above pathways were affected in the 
clinical setting. VEGFr-TKI treatment caused a significant reduction in vessel density 
(CD31), and up-regulation of FGF-2 ligand and vessel-bound MET receptor. Collagen was 
also increased in VEGFr-TKI treated clinical samples.   
In vitro assays demonstrated that VHL gene mutation promoted resistance to SRC TKIs. 
Adding a SRC TKI to VEGFr-TKI therapy had a synergistic anti-tumour effect on 786-O 
xenografts. However, the combination could not prevent growth in tumours that had 
acquired a VEGFr TKI resistant phenotype. There was no evidence that the addition of a 
SRC TKI affected genes implicated in the resistance process.  
Interpretation: VEGFr-TKI treatment is associated with dynamic molecular changes to 
several relevant biomarkers. Targeting any one pathway in isolation may have an 
incremental anti-tumour effect, but because multiple pathways are affected, it is 
perhaps unlikely to result in a sustained improvement in tumour response. 
Heterogeneity of protein expression adds further complication to a targeted approach. 
Collagen deposition increases with VEGFr TKI therapy. Collagen has been shown to 
promote angiogenesis and metastasis. Further investigation is warranted to understand 
whether the addition of anti-fibrotic agents to anti-angiogenic therapy could have an 
incremental benefit on patient outcome.  
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Chapter 1:  
Introduction 
 
  
1.1 Cancer cells and the tumour microenvironment  
Cancer can be thought of as a multistep process in which normal cells evolve 
progressively to a neoplastic state 1. Often this involves malignant cells 
acquiring the ‘hallmarks of cancer’. In their seminal work, Hanahan and 
Weinberg identified six ‘hallmarks’ that drive malignancy 2 including an 
enhanced ability to survive and proliferate. 
More recently, a better understanding of the tumour microenvironment has 
allowed us to recognize the importance of non-malignant cells in tumourgenesis 
3 4. For example, myeloid cells and cancer associated fibroblasts have been 
shown to help promote angiogenesis and escape immune surveillance 5 6. 
Because angiogenesis and metastasis are thought to be key pillars of VEGF-TKI 
(vascular endothelial growth factor-tyrosine kinase inhibitors) resistance, these 
two ‘hallmarks of cancer’ are reviewed in more detail. 
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1.2 Angiogenesis 
Angiogenesis is the formation of a network of blood vessels consisting of a thin 
layer of endothelial cells supported by pericytes and smooth muscle cells. 
Tumour-associated angiogenesis is the formation of vessels that can penetrate 
deep into the malignant tissue helping to supply tumours with oxygen and 
nutrients required for growth and survival 7. The angiogenic process requires the 
production of pro-angiogenic factors at the tumour site, which recruit key 
components of the blood vessels, such as endothelial cells, in addition to 
promoting proliferation and survival of these component cells once at the tumour 
site 7.  
 
The Von Hippel Lindau (VHL) / Hypoxia-Inducible Factor (HIF) pathway plays a 
key role in regulating the expression of several pro-angiogenic factors. Under 
normoxic conditions functional VHL labels HIF transcription factors for 
proteasomal degradation. Under hypoxic conditions, or through loss of functional 
VHL, HIF-alpha is allowed to stabilise, resulting in the constitutive up-regulation 
of pro-angiogenic genes 8.  
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Figure 1.1: VHL mediates expression of pro-angiogenic genes
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Perhaps the most notable pro-angiogenic factor produced by tumours is VEGF, a 
family of signal proteins that initiate cellular responses by binding to tyrosine 
kinase receptors (VEGFRs) located on the cell surface of endothelial cells 9. 
Tumour-associated angiogenesis is thought to be primarily driven by VEGF-A 
(also sometimes referred to simply as VEGF), which binds to VEGFR-1 and 
VEGFR-2 9. VEGFR-2 is believed to be the key mediator of endothelial cell 
response, although VEGFR-1 is thought to play an important role in recruiting 
bone marrow-progenitors 10. VEGFR-1 may also be important for the recruitment 
of pro-angiogenic myeloid cells to the tumour site 10.  
 
In addition to VEGF, FGF-2 (fibroblast growth factor-2) and HGF (hepatocyte 
growth factor) represent two important alternative pro-angiogenic ligands. These 
two alternative pro-angiogenics factors are thought to promote vessel formation 
through direct interaction with their corresponding receptors which are present 
on endothelial cells (FGFR1-4 and MET receptor respectively) 11 12. 
 
While the above mentioned ligands interact directly with endothelial cell 
receptors, other pro-angiogenic factors are thought to promote angiogenesis 
through interactions myeloid cells. A good example is interleukin-8 (IL-8). IL-8 
targets the CXCR1 and CXCR2 receptors, which are thought to be present on 
some endothelial cells. However IL-8 is thought to have a stronger chemotactic 
effect on neutrophils and monocytes 13. Consequently, tumour derived IL-8 could 
potentially promote angiogenesis through direct interaction with endothelial cells, 
but may be more influential through its recruitment of pro-angiogenic myeloid 
cells.  
 
Finally, some molecules can promote angiogenesis without having any direct 
effect on endothelial cells. Cytokines such as GM-CSF or M-CSF, for example, can 
promote angiogenesis through an indirect, pro-inflammatory mechanism, but are 
not thought to have any direct effect on endothelial cell signalling 14. Proteinases 
such as the matrix metalloproteinase family (MMPs) provide another good 
example of this pro-angiogenic concept. MMPs are capable of degrading the 
extracellular matrix (ECM). In this way cell can more easily move through the 
ECM, which could help the recruitment of endothelial cells to the tumour site 15. 
MMPs may also release latent pro-angiogenic factors, such as VEGF, which are 
stored in the ECM. 
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1.3 Metastasis and epithelial-mesenchymal-transition 
The process of metastasis involves several significant steps; the metastatic cell 
must reduce cell-to-cell and cell-to-matrix adhesion, increase motility, acquire 
enough invasive capability to migrate through the extracellular matrix and, if 
migrating though vessels or the lymphatic system, the cell must be capable of 
intravasation and subsequent extravasation. Finally, the cell must be capable of 
survival and proliferation at a distant site.    
By undergoing epithelial-mesenchymal transition (EMT) cells initially anchored at 
the primary site may accomplish many of the processes described above. EMT is 
biological process thought that is thought to be activated during embryogenesis 
and play a physiological role in wound healing and fibrosis.  
As the name suggests, a molecular hallmark of cells undergoing EMT is the 
down-regulation of epithelial markers such as e-cadherin and the up-regulation 
of mesenchymal markers such as n-cadherin and vimentin. Phenotypically this 
process is thought to promote a less adhesive, more motile cell capable of 
penetrating through local tissue. 
Several signaling pathways are thought to promote EMT. Some of these 
pathways include TGF-β, Wnt, Notch, and Hedgehog 16 17 17 18. These pathways 
can converge on the transcription factors Snail, Slug and Twist to promote EMT 
19. Importantly, these EMT-inducing transcription factors have been shown to be 
effected by hypoxia, providing a potential direct link between anti-angiogenic 
therapy and EMT 20 21.  
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1.4 Renal cell carcinoma  
Renal cell carcinoma (RCC) accounts for approximately 90% of all cancers of the 
kidney 22 and these represent approximately 2% of all cancers reported 23. RCC 
is thought to derive from proximal tubule cells 24. Like much of the adult kidney, 
proximal tubule cells derive from the mesoderm during development through a 
process of mesenchymal-epithelial transition 25.   
Inactivation of the von-hippel landau (VHL) gene is by far the most common 
genetic alteration found in renal carcinoma. Deletion or mutation occurs in 
approximately 60% of cases 26, with silencing by promoter methylation present 
in about another 20% of cases 27. VHL is the master regulator of multiple pro-
angiogenic factors. Consequently, RCC patients tend to present with highly 
vascular tumours. 
Clear Cell RCC represents the majority of renal carcinomas. Histologically Clear 
Cell tumors can be identified by clusters of malignant cells, with a clear 
cytoplasm, surrounded by a dense endothelial network. Clear Cell RCC provides 
the focus of this thesis, and the main target of anti-angiogenic therapy. Other 
less common subtypes, such as Papillary Carcinoma and Chromophobe RCC, are 
not susceptible to VHL mutation. Anti-angiogenic therapy does not provide 
standard of care for these subtypes. 
 
1.4.1 RCC treatment options 
As with other cancers, patients presenting with a small localised tumour have a 
significantly better prognosis than more advanced cases. According to data from 
the US National Cancer Data Base, 5 year-survival for patients presenting with 
localised disease is approximately 80%, but this falls to less than 10% for 
patients presenting with metastatic disease. In localised cases, nephrectomy is 
an effective treatment. However, because renal-cell carcinoma is characterised 
by a lack of early-warning signs, a high proportion of patients present with 
metastases 28. Common sites of metastasis include lung, bone, liver and brain. 
 
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 13 
The poor prognosis for patients presenting with metastatic disease can be 
explained, in part, by the lack of effective therapy beyond surgical resection. In 
general, RCC is considered resistant to both chemotherapy and radiotherapy. 
Until the recent emergence of tyrosine kinase inhibitors, immunotherapy, in the 
form of interferon-α or interleukin-2 (Il-2), provided the mainstay of treatment. 
FDA approval of cytokine therapy was based on as series of clinical trials that 
demonstrated response rates of 5-20% and complete response rates of 
approximately 5% 29-31. Complete responses generated by cytokine therapy are 
often durable. These durable responses, albeit in a small proportion of patients, 
provided much of the impetus that led to regulatory approval. Cytokine therapy, 
particularly high dose IL-2 is associated with significant treatment-related 
toxicities including fever, chills, flu like symptoms, myalgia and fatigue. Studies 
investigating high-dose IL-2 required patients to be highly selected with 
excellent performance status. Similar considerations are needed when selecting 
patients suitable for this treatment option in the clinical setting.  
 
 
An improved understanding of the genetics and pathogenesis of RCC has led to 
the emergence of targeted therapy. VHL function is impaired in 60- 70% of RCC 
tumours 26, 27. The regulatory approval of VEGF-TKI therapy for metastatic RCC 
patients has revolutionised treatment strategies and these drugs now provide 
first line standard of care 32. 
 
 
 
 
 
 
 
 
 
1.5 Targeting angiogenesis in renal carcinoma 
 
The development of the first multi-tyrosine kinase inhibitors (TKIs) 32 caused a 
paradigm shift in the treatment of metastatic RCC. Since 2005, the US regulatory 
authorities have approved four anti-angiogenic tyrosine kinase inhibitors for the 
treatment of metastatic RCC; sunitinib, sorafenib, pazopanib and axitinib. In 
addition, the monoclonal antibody, bevacizumab, which targets the VEGF-A 
ligand, received regulatory approval for use in combination with interferon-α. 
Table 1.2 below provides an overview of the key clinical studies investigating 
anti-angiogenic therapies that provided the basis for their adoption as standard 
of care in RCC. 
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Drug / drug 
combination
Previous 
treatment Comparator
Study 
size
Primary 
endpoint
Endpoint 
 met
PFS in months 
(active / 
comparator)
Publication
Sorafenib None Interferon 189 PFS No 5.7 / 5.6
Escudier et al - J Clin
Oncol 2009;27:1280-9
Sunitinib None Interferon 750 PFS Yes 11.0 / 5.0
Rini et al - Lancet 
2012;378:1931-9
Pazopanib None Sunitinib 1110 PFS* Yes 8.4 / 9.5
Motzer et al - N Engl J Med
2013;369:722-31
Axitinib None Sorafenib 288 PFS No 10.1 / 6.5
Hutzon et al - Lancet Oncol
2013;14:1287-94
Bevacizumab + 
interferon None Interferon 732 PFS Yes 8.5 / 5.2
Rini et al - J Clin Oncol 
2008;26:5422-8
Bevacizumab + 
interferon None Interferon 649 PFS Yes 10.2 / 5.4
Motzer et al - N Engl
J Med 2007;356:115-24
Axitinib
TKI or 
cytokines Sorafenib 723 PFS Yes 6.7 / 4.7
Huang et al - Cancer Res 
2010;70:1053-62
Sorafenib Cytokines Placebo 903 PFS Yes 5.5 / 2.8
Motzer et al - Lancet 
2008;372:449-56
Pazopanib
Cytokines 
or none Placebo 415 PFS Yes 9.2 / 4.2
McTigue et al - PNAS 
2012;109:18281-9
  PFS = progression free survival, OS = overall survival, * non-inferiority design, TKI = Sorafenib, sunitinib or pazopanib
 First line treatment
 Second line treatment
 
 
Since VEGFR2 is thought to be the key mediator of endothelial cell response to 
VEGF, the TKIs have been designed, primarily, to inhibit activation of VEGFR-2, 
but all four approved drugs also inhibit VEGFR1 and VEGFR3, to some extent. 
Additional TKIs targeting anti-VEGFR2 are in clinical trials including cediranib and 
tivozanib. 
 
Further to inhibiting VEGF receptors, the TKIs are known to inhibit other tyrosine 
kinases, which may also contribute towards the observed clinical benefit. For 
example, sunitinib inhibits PDGF alpha and beta receptors 33, present on 
pericytes and endothelial cells. Sunitinib also affects receptors, such as the c-Kit 
receptor 33, which are present on myeloid and lymphoid progenitors and play a 
role in their recruitment to the tumour site.  
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1.6 Resistance to anti-VEGF therapy 
 
An early hope of anti-VEGF therapy was that by targeting the tumour 
vasculature, rather than unstable tumour cells, drug resistance would be less 
likely to occur 34. This early hope has not translated into clinical reality. In 
addition to patients presenting with intrinsic (or pre-existing) resistance to 
therapy, tumours can develop resistance after initially responding to therapy 
(acquired resistance). Acquired resistance is the main problem in the RCC 
setting.  The majority of RCC patients enjoy an initial response to therapy, but 
ultimately acquired resistance emerges and tumour progress. Data from the 
pivotal trial leading to the approval of sunitinib in mRCC shows that while 
approximately 50% of patients were deemed as complete or partial responders 
(defined as at least a 30% reduction in the sum of the target lesions), and a 
further 40% experienced stable disease, more than 90% of patients had 
progressive disease within 14 months of starting therapy 32. As yet, no predictive 
biomarkers for VEGF-targeted therapy have been firmly established. However, 
observations from clinical and pre-clinical studies have generated several 
hypotheses as to how tumours are capable of developing the ‘acquired resistance 
phenotype’: 
 
Pre-clinical and clinical studies have revealed a significant increase in circulating 
VEGF levels in patients receiving VEGFR TKI or bevacizumab, an anti-VEGF 
monoclonal antibody 35. Whether this feedback loop contributes to acquired 
resistance is not fully understood. It is, perhaps, less likely to play an important 
role in RCC tumours lacking functional VHL than some other tumour types, since 
VHL null RCC tumours already generate high levels of VEGF prior to treatment 
onset. 
 
In addition to the potential contribution from increased VEGF production, two key 
resistance mechanisms have been proposed; 1) a switch to alternative 
angiogenic pathways 2) increased metastatic potential as a result of treatment. 
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1.6.1 A switch to alternative angiogenic pathways 
 
Placental growth factor (PGF) is another member of the VEGF family members 
that has shown to be increased in patients receiving anti-VEGF therapy. PGF 
binds to VEGFR-1. Consequently, VEGFR-2 focused TKIs may be less capable of 
counteracting the effects of PGF (although the approved TKIs mentioned are 
thought to inhibit VEGFR-1 to some extent). The impact of PGF on resistance 
remains controversial, but PGF has been shown to act synergistically with 
available VEGF ligand 36. 
 
Several anti-VEGF studies have associated increased expression of fibroblast 
growth factor (FGF) family members with tumour rebound and renewed 
angiogenesis. For example, Casanovas et al showed both a correlation of 
increased FGF with renewed angiogenesis and further demonstrated that the 
application of an ‘FGF-trap’, which targets several FGF isoforms could prevent 
this mechanism of vascular relapse 37. More recently, Welti et al demonstrated 
FGF1 and FGF2 were capable of inducing resistance to the VEGFR-2 TKI, 
sunitinib, in vitro 38. Furthermore, the same authors use a 74 patient tissue 
micro-array to demonstrate the presence of FGF2 in both RCC tumour cells and 
the associated endothelium.  
 
Another pro-angiogenic factor suggested as a possible resistance mediator in 
RCC is interleukin-8 (IL-8). Huang et al used 3 different RCC xenograft models to 
show an association between IL-8 levels and tumour rebound during sunitinib 
treatment 39. Furthermore, in one xenograft, using 786-O cells, the authors 
showed that an anti-IL-8 antibody provided a therapeutic benefit in tumours 
displaying an anti-VEGF-resistant phenotype. 
 
 
1.6.2 Promotion of a ‘metastatic phenotype’ 
 
Recent work suggests that anti-angiogenic therapy may promote metastasis, 
potentially undermining any survival benefit conferred by slowing growth of the 
existing tumour 40 41. Metastasis, not the primary tumour kills cancer patients, in 
most cases, yet most anti-VEGF preclinical work has traditionally focused on the 
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effect on the primary tumour, ignoring any impact on metastatic potential 42. But 
two recent papers showed that while anti-VEGF treatment retarded primary 
tumour growth, invasion and metastatic potential were enhanced 40, 41. 
Furthermore, in these pre-clinical studies anti-VEGF treatment was associated 
with shortened survival.  
 
Treatment-induced hypoxia provides one plausible trigger to explain these 
observations. As a consequence of anti-angiogenic therapy, tumour cells may 
respond by activating pro-invasive, pro-metastatic pathways in order to escape 
their hypoxic microenvironment 43. Furthermore, anti-VEGF treatment may select 
for more malignant cells, with higher metastatic potential, which are better 
equipped to survive the hypoxic environment. 
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Figure 1.2: Proposed mechanisms of resistance to VEGF-TKIs  
MVD = Microvessel Density 
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1.6.3 Recruitment of bone marrow derived cells and vasculogenesis 
 
An accumulating body of evidence suggests that non-maligant cells, particularly 
bone marrow derived cells (BMDC) could be involved in anti-VEGF resistance. At 
least three separate mechanisms have been proposed to explain how BMDC 
recruitment can contribute to tumour progression; the latter two are more 
closely linked to potential escape mechanisms:  
 
Firstly, a subgroup of BMDCs, known as myeloid derived suppressor cells, may 
help the tumour escape from a cell mediated immune response 44 45 46. 
 
Secondly, infiltrating BMDCs could promote re-vascularisation by producing 
members of the FGF family, IL-8 and other alternative pro-angiogenic factors.  
 
The third potential mechanism is promotion of vasculogenesis. Vasculogenesis 
can be defined as the de novo production of vessels in situ from circulating 
endothelial progenitor cells. This differs from angiogenesis, which can be defined 
as the sprouting of new vessels from pre-existing ones. Vasculogenesis was 
initially thought to be confined to embryonic development, but recent evidence 
suggests a role in tumour vascularisation, and potentially, anti-angiogenesis 
therapy resistance. For example, Bolontrade et al provided evidence that 
migration of BMDC into Ewing's sarcoma tumours and their subsequent 
differentiation into endothelial cells can contribute to tumour growth 47. 
 
So in addition to helping the tumour evade the immune system BMDCs could 
provide two different mechanisms, one direct and one indirect, to help re-
vascularise the tumour to allow tumour progression despite anti-VEGF treatment.  
 
1.6.4 Metabolic change  
 
Clinical observations using FDG-PET and preliminary animal studies suggest that 
changes in tumour metabolism may play a role in undermining anti-VEGF 
therapy. At this stage, this work is hypothesis-generating and needs further 
validation. Nevertheless work carried out by the author of this thesis in 
collaboration with others (but not included in the results section of this thesis) 
aimed to explore this hypothesis 48.  
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1.7 The potential of SRC inhibitors in renal cancer 
 
Some of the ongoing work to establish important anti-VEGF resistance 
mechanisms has been highlighted. None of these potential mechanisms have 
been firmly established and more work is needed to validate which pathways are 
important in the different cancer types. Increased knowledge could lead to 
improved patient outcome through both improved initial patient selection and a 
more durable therapeutic response in treated patients. One potential therapeutic 
strategy would be to combine a SRC inhibitor with the existing anti-VEGF 
therapies. A background to SRC is given to better understand the rationale for 
this combination: 
 
 
1.7.1 SRC background 
 
In 1911, Peyton Rous described a virus that appeared to induce tumours in 
chickens 49. This hypothesis remained controversial until 1955 when v-Src, a 
rous sarcoma virus gene was shown to be capable of inducing tumours 50.  
 
v-Src and its human cellular counterpart c-Src encode a non-receptor tyrosine 
kinase, SRC. SRC proteins contain four src homology domains SH1-SH4 51, with 
SH1 containing the kinase domain. Full activation requires auto-phosphorylation 
of a tyrosine residue (Tyr419 in human c-Src). Inactivation can occur through 
phosphorylation of Tyr530, which causes the c-terminal domain to bind back to 
its SH2 domain, locking the protein in a closed structure with the kinase domain 
inaccessible.  
SRC protein is one of 9 members of the SRC kinase family. The other SRC kinase 
proteins are FYN, YES, BLK, YRK, FGR, HCK, LCK and LYN 52. SRC is the protein 
most often implicated in cancers 52 but the potential for SRC inhibitors to impact 
other family members should be noted. By inhibiting other SRC family members, 
particularly FGR, HCK and LYN, SRC inhibitors may impact the myeloid 
compartment in addition to tumour cells 53. 
 
Over-expression of SRC protein and / or an increase in its activity has been 
observed in numerous cancer types 54. For example, colorectal cancer shows a 
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progressive increase in c-SRC activity as the tumour stage advances. Colorectal 
metastatic lesions often have the highest levels of c-SRC activity, indicating a 
potential role for c-SRC in mediating tumour progression and metastasis 55. 
Preclinical models have shown SRC can impact tumour cell proliferation, 
survival, metastasis and angiogenesis:  
 
Perhaps most notable is SRC’s apparent ability to effect motility and adhesion, 
which is mediated in a large part through its interaction with the proteins that 
make up the focal adhesion complex. Focal adhesions form next to the cell 
membrane and allow integrins to link the actin cytoskeleton to extracellular-
matrix (ECM) proteins. SRC interacts directly with the focal adhesion kinase, 
FAK. The SRC-FAK complex interacts with several other substrates, including 
CAS, paxillin and p190Rho 56. These cytoskeletal proteins assemble into 
supramolecule structures, associate with stress fibers such as actin, and, 
dynamically regulate the shape and motility of the cell. In addition to the focal 
adhesion complex, adheren junctions can also regulate adhesion and motility. 
Again SRC is a principle player in the formation of these subcellular structures. 
Adheren junctions regulate cell-to-cell adhesion (rather than cell-to-ECM 
controlled by focal adhesion). c-SRC can disrupt adheren junctions by 
preventing E-cadherin localisation and important contact points. Further to their 
role in cell–matrix adhesion, SRC and member of the focal adhesion complex, 
participate in a two way cell-signaling process that can influence survival, 
proliferation and gene transcription 57. For example, evidence suggests that 
SRC-FAK signaling to c-JUN can promote the expression of matrix 
metalloproteinases such as MMP2 and MMP9 52. These proteases help degrade 
the ECM facilitating and cell migration. In this way, SRC can increase metastatic 
potential at multiple stages of the metastatic process; firstly by reducing 
adhesion and promoting cells release both from the ECM and other cells and 
secondly by up-regulating proteases to facilitate invasion and movement to 
distant sites. 
 
While, SRC has consistently demonstrated the ability to promote cell migration 
across in a wide range of cell lines, its ability to influence proliferation and 
survival is much less consistent. Several mechanisms have been proposed to 
explain how SRC activation can promote proliferation including the abrogation of 
MYC requirement at G0/G1 and decreased b-catenin binding to cyclin D1 52. 
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However, evidence from studies using SRC inhibitors seems to indicate that the 
effect on proliferation is cell line specific.  
 
Angiogenesis is regulated by multiple cytokines that creating a cascade that 
favours endothelial cell migration and proliferation in the tumour 
microenvironment. SRC has been associated with increased expression of the 
pro-angiogenic factors IL-8 and VEGF, the latter is thought to be mediated 
through STAT3 activation 52. Furthermore, SRC inhibition may reduce endothelial 
migration to the tumour site through mechanisms described above including, 
reduced motility of endothelial cells and reduced expression of MMP2 and MMP9 
52, 58.  
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Figure 1.3: SRC mediates molecular pathways involved in angiogenesis 
and metastasis 
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1.7.2 SRC inhibition and VEGFr-TKIs; the rationale for combination 
The EMT process potentially provides a direct link between VEGF-TKIs and 
metastasis. Perhaps the most obvious mechanism by which SRC inhibitors may 
synergistic combination with VEGF-TKIs is to counteract this potential promotion 
of a metastatic phenotype. SRC inhibitors could increase adhesion, reduce 
motility and regulate production of pro-metastatic factors such as the MMPs. 
Tumour re-vascularisation is thought to promote resistance to VEGF-TKIs. SRC 
inhibitors could help counteract this process through several mechanisms. SRC 
has been proposed to regulate VEGF through the STAT3 pathway and also 
through VHL stabilisation. SRC inhibitors may also directly effect endothelial 
cells reducing their ability to survive, proliferate and migrate to the tumour site 
58. Finally, SRC has been suggested to regulate MMP production 52, 58. Finally, 
MMPs are not only important in metastasis. By down-regulating MMP production, 
SRC inhibitors could limit endothelial recruitment and reduce the release of 
latent pro-angiogenic factors, such as VEGF. 
The recruitment of BMDCs may help promote resistance. SRC inhibitors could 
also limit BMDC recruitment 58 both the motility of these cells or by impacting 
their production in the bone marrow 59.  
Finally, IL-8 has been implicated in RCC resistance 39. SRC has been proposed as 
an important regulator of this gene 60. Reduced IL-8 production through SRC 
inhibition could counteract this proposed mechanism of resistance.  
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Figure 1.4: Potential mechanisms of action for SRC TKIs targeting VEGF-TKI resistance 
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1.8 Aims and objectives 
 
The primary aim of this project is to further investigate the molecular pathways 
driving resistance to VEGF-TKI therapy and determine whether SRC inhibitors 
can help counteract the onset of resistance. Our hypothesis that SRC inhibitors 
may provide a synergistic combination with anti-VEGF therapy in this setting is 
based on an extensive body of work (albeit in non-renal models) that suggests 
SRC is capable of enhancing metastatic potential in addition to regulating 
molecules associated with angiogenesis. The principal objectives of this thesis 
are to: 
 
1. Develop a preclinical model of ‘evasive resistance’. 
 
2. Investigate the molecular pathways driving resistance in this preclinical 
model. 
 
3. Using RCC patient tissue, determine whether the preclinical model is 
representative of the clinical resistance process. 
 
4. Use the preclinical model of resistance to investigate whether SRC 
inhibitors can be effective in this setting. 
 
5. Determine whether there are subgroups of RCC patients that are more 
likely to respond to SRC therapy. 
 
The preclinical work carried out for this PhD complements an ongoing 130 
patient, phase II clinical study comparing the effect of combined SRC inhibitor 
(AZD0530) and VEGF inhibition (cediranib) to VEGF inhibition alone in Sunitinib 
refractory patients (Principal Investigator; Dr Tom Powles, Barts and the 
London). 
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Chapter 2: 
Materials and Methods 
 
 
2.1 Cell culture: 
 
In vitro experiments and xenogaft studies were performed with RCC cell lines 
ACHN, Caki-1, 786-O and A-498 originally obtained from American Type Culture 
Collection (Manassas, VA).  
 
Cell lines  Origin  VHL status  HIF‐1a status 
ACHN 
Metastatic (pleural effusion) lesion of a 22 year old, male, 
caucasion patient  Wild‐type  Wild‐type 
786‐O  Primary lesion of a 58 year old, male, caucasion patient  VHL null  HIF‐1a null 
CAKI‐1  Metastatic (skin) lesion of a 49 year old, male, caucasion patient  Wild‐type  Wild‐type 
A498  Taken from a lesion of a 52 year old, female, caucasion patient  VHL null  HIF‐1a null 
 
RCC4-vector and RCC4-VHL were obtained from the European Collection of Cell 
Cultures (London, UK). DNA fingerprinting was carried out to avoid 
contamination or misidentification.  
 
Between experiments, cells were stored in 10% Dimethyl Sulfoxide (DMSO), 
30% heat-inactivated fetal calf serum, 60% RPMI 1640 in liquid nitrogen. For in 
vitro assays, cells were thawed and maintained in RPMI 1640 media 
supplemented with 10% heat-inactivated fetal calf serum (PAA) and 1% 
streptomycin (PAA) at 37°C in a humidified atmosphere of 10% CO2, 21% O2. 
For HIF-stabilizing experiments that required hypoxic conditions, cells were 
transferred to a humidified atmosphere with 10% CO2, 1% O2.  
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2.2 Reagents for in vitro assays: 
 
Dasatinib (LC laboratories) and Saracatinib (AZD0530, AstraZeneca) were 
dissolved in 20mg/ml DMSO (stock) and desired dose levels were achieved by 
serially diluting the stock by adding medium prior to conducting in vitro assays. 
Appropriate DMSO-only controls were utilized as required. For HIF-stabilizing 
assays, dimethyloxalylglycine (Sigma) was dissolved in distilled water at 20 
mg/ml before diluting in RPMI media to required concentrations.  
 
 
 
Kinase  Mean IC50, nM/L, mean 
Src                 2.7 
Lck                   < 4 
Yes                   4 
EGFR L861Q      4 
Lyn                  5 
EGFR L858R      5 
Fyn                  10 
Fgr                   10 
Blk                   11 
Abl                  30 
EGFR                66 
Kit                    200 
EphA2              236 
Csk                  >1000 
 
Table 2.1: Inhibitory activity of AZD0530 on isolated tyrosine kinases. Adapted from 
Green et al 61. 
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Kinase   IC50 nM/L), mean  
 Lck  0.4 
 Src  0.5 
 Yes  0.5 
 Abl  <1 
 c‐kit  5 
PDGFR‐beta  28 
 p38  100 
 EGFR  180 
 HER2  780 
 MEK  >1000 
 
Table 2.2: Inhibitory activity of dasatinib on isolated tyrosine kinases. Adapted from 
Lombardo et al 62. 
 
 
 
Kinase  IC50 nM/L), mean  
      VEGFR family 
KDR (VEGFR-2)  <1 
Flt-1 (VEGFR-1) 5 
Flt-4 (VEGFR-3)  3 
     PDGFR family 
c-Kit  2 
PDGFR-h  5 
PDGFR-a  36 
CSF-1R  11 
Flt-3 >1   
    Representatives from other kinase families 
FGFR1  26 
Src  13 
Abl  26 
 
Table 2.3: Cediranib (AZD2171) inhibition of VEGF receptor tyrosine kinase activity and 
selectivity profile. Adapted from Wedge et al 63. 
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Kinase  IC50 (nM/L), mean  
     VEGFR family  
VEGFR2  38 
VEGFR1 15 
VEGFR3 30 
     PDGFR family  
c-Kit  <10 
PDGFR-beta 55 
PDGFR-alpha 69 
CSF-1R  35 
Flt-3  21 
    Representatives from other kinase families  
FGFR1  675 
Src  1000 
Abl  610 
 
Table 2.4: Sunitinib (SU-11248) inhibition of VEGF receptor tyrosine kinase activity and 
selectivity profile. Adapted from Roskoski et al 33. 
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2.3 Cell viability assays:  
 
To measure cell proliferation or cytotoxicity a colorimetric assay (Promega) was 
used. This assay uses a tetrazolium compound (MTS) to assess cell viability. For 
MTS assays, cells were seeded at 3-6 x 103 cells per well on 96-well plates and 
cultured in 100ul of RPMI-media overnight. After 24 hours, 100ul of dasatinib or 
saracatinib was added to achieve a range of final concentration between 0 and 
2.5uM.  
 
Cell viability was determined at 24-72 hours following the manufacturer’s 
protocol (Promega); briefly, after 24 or 72 hours, media was removed by 
shaking the 96 well plate. 100ul of MTS reagent was added and plates were 
incubated between 2-4 hours or until controls measured had an optimetric 
density (OD) value of 1.5-1.8 using an ELISA multi-plate reader set to an 
absorbance of 490nm.  
 
2.4 Migration assays:  
 
Scratch assays were performed in 6-well plates. In general, 7.5 x 104 cells per 
well were plated and incubated for 24-48 hours until cells formed a confluent 
monolayer. A cross was scratched into the monolayer using the tip of a 1ml 
pipette, cells were washed in PBS and 2ml of RPMI + 10% FCS media was 
added, which contained between 0nM, 10nM, 50nM or 250nM dasatinib. An 
image was taken immediately after media was added and cells were incubated 
for 18 hours. A further imaged was taken after 18 hours and dynamic changes 
in cell migration were observed by comparing the size of the scratch at the two 
time points. This assay was performed in triplicate for each drug concentration. 
 
For transwell migration assays, cells were trypsinised, spun down, re-suspended 
in serum-free media and counted using a haemocytometer. 2.5 x 105 cells were 
added to each transwell and incubated for 3 hours to allow cells to adhere to the 
transwell membrane. All media was removed before 200ul of serum-free media 
containing 0nM, 10nM, 50nM or 250ul of dasatinib was added to the upper 
chamber of the transwell. The lower chamber contained 500ul of media with the 
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identical drug concentration, but with the addition of 5% fetal calf serum, which 
served as a chemoattractant. Cells were incubated at 37C for 18 hours before 
cells that had migrated through the membrane were fixed, stained with 
haematoxylin and counted.  
 
2.5 Western blots:  
 
Cell lysates were harvested in PBS containing 1% triton and 1% protease 
inhibitor.  A Bradford assay (Bio-Rad) was used to quantify protein levels. For 
immuno-blotting, 30µg of protein was resolved in 10% SDS polyacrylamide gel 
at 100V for 120 minutes. Protein was transferred to nitrocellulose membrane 
(Bio-Rad) at 0.2A for 90 minutes. Membranes were blocked in 1% BSA for 60 
minutes before incubation overnight with the primary antibody. Membranes 
were washed in 1% TBS Tween for 5 minutes three times and incubated with 
the appropriate secondary antibody for 60 minutes. Membranes were washed in 
1% TBS Tween for 5 minutes three times before proteins were revealed using 
chemiluminescent HRP substrate (Millipore). Membranes were re-incubated with 
a primary antibody targeting alpha smooth muscle actin to provide a loading 
control.  
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2.6 In vivo studies: 
 
 
2.6.1 ACHN pilot study 
 
ACHN xenografts were established in 6-8 week old female SCID mice (Charles 
River) by s.c. injection of 5 × 106 tumour cells in 200 ul PBS into the animals 
right flank. To test the effect of dasatinib on tumour growth, animals were 
randomised (1:1) 7 days post inoculation into two treatment groups (n=5); 
daily dasatinib 10mg/kg body weight by oral gavage or vehicle control. Dasatinib 
was prepared freshly each week in 50:50 propylene glycol/water, which also 
served as the vehicle. 
 
ACHN cells were luciferase-tagged to allow tumour measurement by IVIS 
imaging (Caliper Life Sciences). Twice a week mice underwent intraperitoneal 
injection with 150 mg/kg D-luciferin. Mice were anaesthetized by isofluorane 
and tumours imaged 8 minutes after luciferin injection. Bioluminesence was 
quantified using Living Image software (Caliper Life Sciences). 
 
2.6.2 Tolerability studies: 
 
Prior to 786-O or A498 xenograft anti-tumour studies, a tolerability study was 
undertaken to confirm the planned drug dose levels were well tolerated in 6-8 
week old female SCID mice (AstraZeneca). Tumour-free mice (n=2) were 
treated with sunitinib (40mg/kg) and a combination of cediranib and saracatinib 
(3mg/kg + 25mg/kg) and body weight was measured daily. The dose level of 
sunitinib (40mg/kg) in both the tolerability studies and subsequent anti-tumor 
studies was chosen to match the protocol used by Huang et al 39. Cediranib and 
saracatinib dose levels were selected based on previous work conducted by 
AstraZeneca. Specifically, for saracatinib, the 25mg/kg dose is believed to be 
the minimal dose that achieves complete SRC inhibition in mice. The 3mg/kg 
dose for cediranib was based on previous pharmacokinetic work that suggested 
this dose best represented the dose level used in the clinic. 
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2.6.3 786-O pharmacodynamic xenograft studies (PD studies): 
 
A PD study was undertaken to assess the pharmacodynamic effect of sunitinib, 
cediranib and saracatinib on mice harbouring 786-O tumours. 786-O xenografts 
were established in 6-8 week old female SCID mice (AstraZeneca) by s.c. 
injection of 5 × 106 tumour cells in 200 ul 50:50 PBS/Matrigel (Becton 
Dickinson). 30 days post inoculation (tumour volumes 0.2-0.8 cm3) tumours 
were left for 30 days until animals were randomised into treatment groups (n = 
7 for the vehicle group and n= 5 for all other treatment groups).  Animals were 
underwent short-term chronic dosing with saracatinib (25mg/kg), cediranib 
(3mg/kg), sunitinib (40mg/kg) or vehicle (1% polysorbate 80), which involved 
administration once daily by oral gavage for 4 days and necropsies took place 2 
hours after the final dose. Tumour tissue was taken for pharmacodynamic 
analysis; tumours were cut into half with one half frozen in liquid nitrogen (used 
later for RNA analysis) and the other half was paraffin-embedded for IHC 
analysis. Bone marrow samples were harvested for flow cytometric 
measurement of myelosuppression. Plasma was taken and stored at -80C for 
subsequent cytokine analysis.  
 
2.6.4 786-O and A498 anti-tumour studies: 
 
To measure the effect of saracatinib, cediranib and sunitinib on mice harbouring 
786-O tumours, xenografts were established in 6-8 week old female SCID mice 
(AstraZeneca) by s.c. injection of 5 × 106 tumour cells in 200 ul 50:50 
PBS/Matrigel (Becton Dickinson) mix into the animal’s flank. Tumours were 
measured twice weekly with calipers and tumour volumes calculated taking 
length to be the tumour’s longest diameter and width to be the corresponding 
perpendicular diameter using the following formula:  
 
tumour volume = √(length) x (width) x (∏ / 6) 
 
To compare treatment groups, the geometric mean of each cohort was 
calculated. Data were log transformed to take account of any size dependency 
before statistical analysis. 
For anti-tumour studies, animals were randomised into treatment groups (n = 
12-15 per group) when tumours were deemed to have reached a defined 
palpable size; this took place 30 days post inoculation when tumour volumes 
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were 0.2-0.8 cm3. Saracatinib (25mg/kg), cediranib (3mg/kg) and sunitinib 
(40mg/kg) were prepared freshly each week in 1% polysorbate 80, which also 
served as the vehicle control. All drugs and vehicle were administered once daily 
by oral gavage and necropsies took place 2 hours after the final dose was 
administered.  
A similar protocol was followed to assess the anti-tumour affect of sunitinib on 
A498 xenografts. 
 
2.7 Ex-vivo flow cytometric quantification of myeloid cells: 
 
At the termination of both PD and anti-tumour studies, a single femur from each 
animal was removed and bone marrow was flushed with a syringe filled with 1ml 
of 50% PBS/50% FCS. Samples were stored on ice until the completion of 
animal termination and then spun at 1600rpm for 5mins. Supernatant was 
poured off and the pellet re-suspended in 2 ml of PBS. Flow cytometry was 
performed for a total of 50,000 events per sample. Forward scatter and side 
scatter were analysed using previously determined values to gate cells into 4 
cell types; monocytes, granulocytes, lymphocytes and red blood cells. 
 
2.8 Immunohistochemistry: 
 
A tissue microrarray (TMA) was constructed from biopsy and nephrectomy tissue 
samples from three separate Phase 2 trials. For xenograft derived tissue, freshly 
resected xenograft tumours were fixed in 4% w/v formalin overnight and whole 
sections were embedded in paraffin. 
 
The following primary antibodies were used to assess protein expression; CD31 
(1:600, AstraZeneca), FGF-2 (1:100, Peprotech), MET receptor (1:200, 
Invitrogen), CD3 (1:100, Novocastra), CD45 (1:100, Novocastra), Ki67 (1:100, 
Dako), s100a4 (1:150, Cell Signalling). Isotype controls were employed.  
 
MET receptor and FGF-2 protein levels in the RCC patient derived TMAs were 
analysed by the author and a trained histopathologist (Colan Ho-yen and Rukma 
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Doshi respectively). Both the author and histopathologists were blinded at the 
time of scoring. When the score given by the author and histopathologist 
diverged further discussion took place until a consensus was reached. If 
necessary, a 3rd opinion was sought. Scores accounted for the strength of 
protein expression (scored 0 to 3) and the percent of tissue stained. Ki67 scores 
from patient derived TMAs were independently assessed by a trained pathologist 
(Dan Berney). Vessel density (CD31), CD45 or CD3+ve immune cells, were 
quantified using a computerised image analysis system (ARIOL, Applied 
Imaging, Genetix) using visually-trained parameters. Xenograft tissue protein 
expression of S100A4 and Ki67 were quantified using the ARIOL system.  
 
Antigen retrieval conditions, both pH and time, were optimized for the primary 
antibody under investigation. In the majority of cases this optimisation work had 
already taken place prior to the work contained in this PhD. In general, sections 
were de-waxed through graded alcohols to distilled water and immersed in a 
sealed vessel containing 250ml of antigen retrieval buffer (Dako) with a pH of 
between 6 and 9.9 depending on the antibody of interest. Sections were heated 
to a temperature of 110C in a microwave histoprocessor (RHS) for between 2-5 
minutes. Sections were then allowed to cool in running water for approximately 
15 minutes.  For s100a4, MET receptor and Ki67 staining of RCC patient tissue, 
antigen retrieval took place in a pressure cooker; sections or TMAs were left for 
7 minutes once the antigen retrieval buffer had boiled and then allowed to cool 
in running water. 
 
EnVision (Dako) or ABC (Thermo Scientific) kits were used depending on the 
primary antibody used. Sections were incubated with peroxidase blocking 
solution (EnVision) for 10 minutes. If the ABC kit was being used endogenous 
Avidin / Biotin was also blocked at this stage. Sections are incubated with 5% 
Normal Goat Serum for 20 minutes before the primary antibody was added and 
sections were incubated for a further 60 minutes. Sections were rinsed twice in 
0.05% TBS Tween and then incubated with an appropriate secondary antibody 
from either the ABC kit (Thermo Scientific) or EnVision ready-to-use (Dako). 
Slides were rinsed twice in 0.05% TBS Tween and incubated with DAB solution 
for 10 minutes. Sections were rinsed in distilled water, counterstained with 
haematoxylin and dehydrated through graded alcohols to xylene before cover 
slips were attached.   
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2.9 RNA extraction and cDNA synthesis of tumour samples 
for gene expression analysis: 
 
At necropsy tumour samples cut in half with one half snap frozen transferred to 
a -80C freezer for gene expression analysis. For RNA extraction, 30-50 mg of 
tumour samples was taken and placed in 2ml round bottom tubes containing a 
ball bearing. 600ul of RLT lysis buffer (qiagen) containing -mercaptoethanol 
was added to each sample before tissue was homogenised. 600ul of 
homogenate was transferred to a new tube and spun down before supernatant 
was transferred to a fresh tube.  
 
Total RNA was extracted using a QIAcube (Qiagen) following the manufacturer’s 
protocol. RNA concentrations were quantified on a NanoDrop and normalised to 
250ng/ul by adding RNase-free water (Qiagen). RNA was assessed using for 
quality control purposes (Agilent’s 2100 Bioanalyser Instrument with Nano Chip 
Assay). For gene expression analysis an RNA integrity number value (RIN value) 
of 6–10 was considered acceptable.   
 
First strand cDNA samples from 61 different xenograft tumours were selected 
for gene expression analysis (n=6 for treatment groups and n=7 or 8 for the 
vehicle groups). Selection was based on the RIN value and tumour size. For 
treatment groups the 6 samples with acceptable RIN values closest to the mean 
tumour volume in that treatment group were selected for gene expression 
analysis. cDNA synthesis was carried out using the Applied Biosystems High 
Capacity cDNA Reverse Transcription Kit on a thermal cycler as per the 
manufacturer’s instructions. 
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2.10 Gene expression analysis: 
 
Pre-amplification of cDNA samples was performed using the TaqMan PreAmp 
Master Mix using 1.25µL of cDNA in a 5 µL reaction. After 14 cycles pre-
amplified cDNA was stored at −20°C until needed. Pre-amplified cDNA was 
added to the 2x TaqMan Universal Master Mix and loaded into a 24x24 dynamic 
array chips (Fluidigm). Primer probes were also loaded into the array chips and 
the chip was primed in a NanoFlex Controller (Fluidigm). High throughput RT-
PCR analysis was carried out using a BioMark Real-Time PCR System (Fluidigm). 
The cycling program consisted of 10min at 95°C followed by 40 cycles of 95°C 
for 15 sec and 1 min at 60°C.  
 
The following human and mouse-specific probes were used to examine the effect 
of drug treatment on the tumour compartment and the host compartment. 
Human-specific and mouse-specific probes were validated by AstraZeneca prior 
to the onset of the work contained in this thesis using human and murine cell 
lines. 
 
Human-specific probes          Mouse-specific probes 
Gene Symbol Assay ID    Gene Symbol Assay ID 
ACVR1 Hs01090689_m1    Acta2 Mm00725412_s1 
ACVR1B Hs03676620_s1    Acvr1b Mm03053291_s1 
ACVR1C Hs00377065_m1    Acvr1c Mm01331057_m1 
ACVRL1 Hs00163543_m1    Acvrl1 Mm01300353_g1 
ANGPT1 Hs00375823_m1    Angpt1 Mm00456498_m1 
ANGPT2 Hs01048043_m1    Angpt2 Mm00545822_m1 
AXL Hs01064436_m1    Axl Mm00437221_m1 
BMP10 Hs03676570_m1    Bmp10 Mm01183889_m1 
BMP2 Hs00154192_m1    Bmp2 Mm01340178_m1 
BMP4 Hs03676628_s1    Bmp4 Mm03676636_s1 
BMP6 Hs01099596_m1    Bmp6 Mm01332882_m1 
BMPR1A Hs01034913_g1    Bmpr1a Mm01208758_m1 
BMPR1B Hs01010965_m1    Bmpr1b Mm03053312_s1 
BMPR2 Hs00176148_m1    Bmpr2 Mm00432129_m1 
BSG Hs00936295_m1    Bsg Mm00814798_m1 
CACNA1G Hs00367969_m1    Cacna1g Mm00486572_m1 
CACNA1H Hs01103523_m1    Cacna1h Mm00445382_m1 
CACNA1I Hs01096205_m1    Cacna1i Mm01299026_m1 
CCL17 Hs00171074_m1    Ccl12 Mm01617100_m1 
CCL2 Hs00234140_m1    Ccl17 Mm00516136_m1 
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CCL22 Hs01574247_m1    Ccl2 Mm00441242_m1 
CCL3 Hs00234142_m1    Ccl22 Mm00436439_m1 
CCL4 Hs00237011_m1    Ccl3 Mm00441258_m1 
CCL5 Hs00982282_m1    Ccl4 Mm00443112_m1 
CCL7 Hs00171147_m1    Ccl5 Mm01302428_m1 
CD82 Hs00356310_m1    Ccl7 Mm00443113_m1 
CDH1 Hs01013953_m1    Cd82 Mm00492061_m1 
CDH11 Hs00901475_m1    Cdh1 Mm00486906_m1 
CDH12 Hs00362037_m1    Cdh11 Mm00515466_m1 
CDH3 Hs00354998_m1    Cdh12 Mm01165359_m1 
CDH6 Hs00191832_m1    Cdh2 Mm00483213_m1 
CDH8 Hs01031173_m1    Cdh3 Mm01249215_m1 
CHRNA3 Hs01088199_m1    Cdh6 Mm01310024_m1 
CHRNA5 Hs00181248_m1    Cdh8 Mm01242096_m1 
CHRNA7 Hs01063372_m1    Chrna3 Mm00520145_m1 
CHRNB4 Hs00609520_m1    Chrna5 Mm00616329_m1 
CSF1R Hs00234622_m1    Chrna7 Mm01312230_m1 
CSF3 Hs00236884_m1    Chrnb4 Mm00804952_m1 
CSF3 Hs00738431_g1    Csf1r Mm00432689_m1 
CSF3 Hs99999083_m1    Csf3 Mm00438335_g1 
CST3 Hs00264679_m1    Cst3 Mm00438347_m1 
CSTA Hs00193257_m1    Csta Mm01344699_g1 
CSTB Hs00164368_m1    Cstb Mm00432769_m1 
CTSB Hs00947439_m1    Ctsb Mm01310506_m1 
CTSD Hs00157201_m1    Ctsd Mm00515586_m1 
CTSK Hs01080388_m1    Ctsk Mm00484036_m1 
CTSL1 Hs00266474_m1    Ctsl Mm00515597_m1 
CTSL2 Hs00822401_m1    Ctss Mm00457902_m1 
CTSS Hs00175403_m1    Cx3cl1 Mm00436454_m1 
CX3CL1 Hs00171086_m1    Cxcl1 Mm00433859_m1 
CXCL1 Hs00236937_m1    Cxcl10 Mm00445235_m1 
CXCL10 Hs00171042_m1    Cxcl12 Mm00445552_m1 
CXCL12 Hs00930455_m1    Cxcl2 Mm00436450_m1 
CXCL5 Hs00171085_m1    Cxcl5 Mm00436451_g1 
CXCR4 Hs00237052_m1    Cxcr4 Mm01292123_m1 
CXCR7 Hs00664172_s1    Cxcr7 Mm00432610_m1 
CYTL1 Hs01573280_m1    Cytl1 Mm01217841_m1 
DKK3 Hs00951303_m1    Dkk3 Mm00443800_m1 
DLL4 Hs01117333_m1    Dll4 Mm01338020_m1 
EDG1 Hs00173499_m1    Efnb2 Mm01215897_m1 
EDG3 Hs00245464_s1    Eng Mm00468256_m1 
EFNB2 Hs00970627_m1    Enpp2 Mm00516572_m1 
ENG Hs00164438_m1    Entpd1 Mm00515447_m1 
ENPP2 Hs00905125_m1    Ephb4 Mm01201157_m1 
ENTPD1 Hs00169946_m1    F2r Mm00438851_m1 
EPHB4 Hs01119118_g1    F2rl1 Mm00433160_m1 
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 40 
F2R Hs00169258_m1    F2rl3 Mm00433161_g1 
F2RL1 Hs00173741_m1    Fgf1 Mm01258325_m1 
F2RL3 Hs01006385_g1    Fgf15 Mm00433278_m1 
FGF1 Hs00361126_m1    Fgf17 Mm00433281_g1 
FGF17 Hs03676568_gH    Fgf18 Mm03676637_s1 
FGF18 Hs03676581_s1    Fgf2 Mm01289199_m1 
FGF19 Hs00391591_m1    Fgf5 Mm03053745_s1 
FGF2 Hs00266645_m1    Fgf6 Mm01183111_m1 
FGF5 Hs03676587_s1    Fgf8 Mm03676635_mH 
FGF6 Hs00907866_m1    Fgf9 Mm01319105_m1 
FGF8 Hs01097227_g1    Flt1 Mm00438980_m1 
FGF8 Hs03676619_s1    Flt3 Mm00438996_m1 
FGF9 Hs03676566_mH    Flt4 Mm00433337_m1 
FLT1 Hs01052936_m1    Fzd4 Mm03053556_s1 
FLT3 Hs00975659_m1    Fzd5 Mm00445623_s1 
FLT4 Hs01047679_m1    Gas6 Mm00490378_m1 
FZD4 Hs03986777_s1    Gdf2 Mm00807340_m1 
FZD5 Hs00361869_g1    Gpr116 Mm01269030_m1 
GAS6 Hs00181323_m1    H28 Mm00518988_m1 
GDF2 Hs00211913_m1    Hdgf Mm00725733_s1 
HDGF Hs00610315_gH    Hgf Mm01135184_m1 
HEY1 Hs01114113_m1    Hif1a Mm00468875_m1 
HGF Hs00300159_m1    Hpse Mm00461768_m1 
HIF1A Hs00936368_m1    Hspa5 AIAAC6K         
HSPA5 Hs00946084_g1    Id1 Mm03676649_s1 
ID1 Hs00704053_s1    Id2 Mm00711781_m1 
ID1 Hs03676575_s1    Id3 Mm01188138_g1 
ID2 Hs00747379_m1    Id4 Mm00499701_m1 
ID3 Hs00171409_m1    Ifit1 Mm00515153_m1 
ID4 Hs02912975_g1    Il1a Mm99999060_m1 
IFI44L Hs00199115_m1    Il1b Mm01336189_m1 
IFIT1 Hs01911452_s1    Il1r1 Mm00434237_m1 
IL1A Hs99999028_m1    Il1rn Mm01337566_m1 
IL1B Hs99999029_m1    Il6 Mm99999064_m1 
IL1R1 Hs00991010_m1    Il6ra Mm00439653_m1 
IL1RN Hs00893626_m1    Il8rb Mm00438258_m1 
IL6 Hs99999032_m1    Itga5 Mm00439797_m1 
IL6R Hs00169842_m1    Itgam Mm00434455_m1 
IL6R Hs00794121_m1    Itgav Mm00434506_m1 
IL8 Hs00174103_m1    Kcnh1 Mm01316769_m1 
IL8RA Hs00174146_m1    Kcnk2 Mm01323942_m1 
IL8RB Hs00174304_m1    Kcnk9 Mm02014295_s1 
ITGA5 Hs00233743_m1    Kdr Mm01222419_m1 
ITGAV Hs00233808_m1    Kiss1 Mm03058560_m1 
KCNH1 Hs00924320_m1    Kit Mm00445212_m1 
KCNK9 Hs00363153_m1    Lpar1 Mm00439144_m1 
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KDR Hs00176676_m1    Lpar1 Mm03986786_m1 
KISS1 Hs00158486_m1    Lpar3 Mm01312593_m1 
KIT Hs00174029_m1    Mertk Mm01336149_m1 
LPAR1 Hs00954504_m1    Met Mm00434924_m1 
LPAR1 Hs03986771_m1    Mgp Mm00485009_m1 
LPAR3 Hs00173857_m1    Mmp13 Mm01168713_m1 
MERTK Hs00179024_m1    Mmp2 Mm03928978_m1 
MET Hs00179845_m1    Mmp7 Mm01168420_m1 
MGP Hs00969490_m1    Mmp9 Mm00442991_m1 
MMP13 Hs00233992_m1    Mst1 Mm01229834_m1 
MMP2 Hs00234422_m1    Mst1r Mm00436365_m1 
MMP7 Hs01042796_m1    Notch1 Mm00435249_m1 
MMP9 Hs00957555_m1    Notch3 Mm00435270_m1 
MST1 Hs00360684_m1    Nrp1 Mm00435372_m1 
MST1R Hs00899925_m1    Nrp2 Mm01254530_m1 
NOTCH1 Hs00413187_m1    Nt5e Mm01144394_m1 
NOTCH3 Hs01128541_m1    Pdgfa Mm01205760_m1 
NRP1 Hs00826128_m1    Pdgfb Mm01298578_m1 
NRP2 Hs00187290_m1    Pdgfc Mm00480205_m1 
NT5E Hs01573922_m1    Pdgfd Mm00546829_m1 
PDGFA Hs00236997_m1    Pdgfra Mm01211694_m1 
PDGFB Hs00966526_m1    Pdgfrb Mm00435546_m1 
PDGFC Hs00211916_m1    Pecam1 Mm00476702_m1 
PDGFD Hs00937332_m1    Pgf Mm00435613_m1 
PDGFRA Hs00183486_m1    Plat Mm00476931_m1 
PDGFRB Hs00182163_m1    Plau Mm00447054_m1 
PGF Hs01119262_m1    Plaur Mm01149438_m1 
PLAT Hs00263492_m1    Plg Mm01312967_m1 
PLAU Hs01547054_m1    Prkce Mm00440894_m1 
PLAUR Hs00182181_m1    Prkd1 Mm00435790_m1 
PLG Hs00264877_m1    Prkd2 Mm01264603_m1 
PRKCE Hs00942878_m1    Prok2 Mm01182451_m1 
PROK2 Hs01587689_m1    Ptprj Mm01327824_m1 
PTPRJ Hs01119326_m1    Ralbp1 Mm00485718_m1 
RALBP1 Hs00799096_s1    Rhoa Mm01228062_g1 
RHOA Hs01051295_m1    Rhob Mm03676631_s1 
RHOB Hs03676562_s1    Rhoc Mm03928976_mH 
RHOC Hs00747110_s1    Rpsa Mm00726662_s1 
RPSA;RPSAP Hs00347791_s1    S100a4 Mm00803371_m1 
S100A4 Hs01569256_m1    S1pr1 Mm00514644_m1 
SERPINB2 Hs00234032_m1    S1pr3 Mm00515669_m1 
SERPINB5 Hs00985285_m1    Serpinb2 Mm00440905_m1 
SERPINE1 Hs01126604_m1    Serpinb5 Mm00436763_m1 
SGK1 Hs00178612_m1    Serpine1 Mm00435860_m1 
SGK2 Hs00367639_m1    Serpine2 Mm00436753_m1 
SGK3 Hs00179430_m1    Shh Mm03053649_s1 
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SHH Hs00179843_m1    Snai1 Mm00441533_g1 
SNAI1 Hs00195591_m1    Snrk Mm00505255_m1 
SPHK1 Hs00184211_m1    Sphk1 Mm01252544_m1 
SPHK2 Hs00219999_m1    Sphk2 Mm00445021_m1 
SPP1 Hs00167093_m1    Tek Mm01256892_m1 
SPP1 Hs00960641_m1    Tgfb1 Mm00441724_m1 
TEK Hs00176096_m1    Tgfbr1 Mm00436964_m1 
TGFB1 Hs00171257_m1    Thbs1 Mm01335418_m1 
TGFBR1 Hs00610318_m1    Tie1 Mm00441786_m1 
THBS1 Hs00962914_m1    Timp1 Mm00441818_m1 
TIE1 Hs00178500_m1    Timp3 Mm01224941_m1 
TIMP1 Hs99999139_m1    Trpc1 Mm00441975_m1 
TIMP3 Hs00165951_g1    Trpc6 Mm01176083_m1 
TRPC6 Hs00395102_m1    Trpm8 Mm01299593_m1 
TRPM8 Hs00375481_m1    Trpv2 Mm00449223_m1 
TRPV2 Hs00901640_m1    Twist2 Mm00492147_m1 
TRPV4 Hs01099348_m1    Tyro3 Mm00444547_m1 
TWIST2 Hs03986784_s1    Vegfa Mm00437304_m1 
TYRO3 Hs03986773_m1    Vegfb Mm00442102_m1 
VEGFA Hs00900054_m1    Vegfc Mm01202432_m1 
VEGFB Hs00957980_g1    Vim Mm01333430_m1 
VEGFC Hs00153458_m1    Wnt1 Mm00810320_s1 
VIM Hs00958112_g1         
WNT1 Hs03986774_s1         
 
Delta Ct values for each gene were calculated with reference to human/murine-
specific 18s probes (AstraZeneca). A computer script using the R programming 
language was written to display Delta Ct values as a heatmap.  
Principal component analysis was carried out for quality control purposes. 
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2.11 ELISA (Enzyme-Linked ImmunoSorbent Assay) 
The affect of drug treatment of serum levels of human PGF were investigated by 
ELISA (Human Quantikine ELISA, R&D systems). Serum was collected at study 
termination and stored at -80C. Samples were thawed on ice and 100µl of 
serum was added to each well of the 96-well plate. Samples were incubated for 
2 hours at room temperature before being washed as per the manufacturer’s 
instructions. 200µl of conjugate was added and incubated for a further 2 hours 
before another round of washing. 200µl substrate was added and the plate 
incubated for 20 minutes before 50µl of stop solution was added. Samples were 
transferred to a multi-plate reader (570nm absorbance) and levels of PGF 
quantified with reference to the manufacturer’s standard. Tumour-derived PGF 
levels were normalised with reference to tumour size at study termination. 
 
2.12 Collagen staining 
To determine collagen content in both xenograft and RCC patient tissue, whole 
sections were dewaxed and hydrated through graded alcohols to distilled water. 
Slides were incubated in sirius-red for one hour before washing in acidified water 
(acetic acid diluted to 1/200 with distilled water). Slides were rinsed twice in 
0.05% TBS Tween and incubated with DAB solution for 10 minutes. Sections 
were rinsed in distilled water and dehydrated through graded alcohols to xylene 
before cover slips were attached. Collagen was quantified with the ARIOL 
system using visually trained parameters. 
 
2.13 Statistics 
A Student's two-tailed t-test was used to investigate the affect of drug 
treatment versus control. A p-value of <0.05 was considered to be statistically 
significant.  
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Chapter 3: 
Investigating the effect of VEGFR-TKI therapy on 
matched pairs of RCC patient tissue 
 
 
3. 1 Introduction 
   
 
The advent of VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) has 
revolutionised the treatment of metastatic renal cell carcinoma (mRCC). The 
TKIs sunitinib and pazopanib are now established as first line therapy. Both 
these drugs are thought to act primarily as anti-angiogenic agents, targeting 
VEGF receptors located on tumour vessels. Direct anti-tumour effects and the 
ability to enhance immune response may also contribute to the observed clinical 
efficacy 64 46 65. 
 
An initial hope of anti-angiogenic therapy was that targeting tumour vessels, 
rather than inherently unstable tumour cells, could help prevent drug resistance 
occurring. Clinical experience has been very different 66. Intrinsic resistance, 
although less common in mRCC than other tumour types, occurs in 
approximately 20% of cases 67. Patients that do benefit from an initial response 
invariably progress at some stage. Numerous resistance mechanisms have been 
proposed. Perhaps most prominent is the hypothesis that tumours can 
compensate for VEGF inhibition by switching to alternative angiogenic factors 
such as fibroblast growth factor-2 (FGF-2) 68 69 or the HGF/MET receptor 
pathway 70 71.   
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3.2 Aim of chapter 
 
A better understanding of the resistance mechanisms underlying tumour 
progression has been hampered by; (1) lack of access to treated patient tissue 
and (2) the lack of a representative preclinical model. In this chapter we try to 
address both issues. 
 
As a result of three recent clinical trials, we gained access to VEGFR-TKI-treated 
tissue samples 72 73 74. Pre-treatment biopsies were taken prior to onset of 
sunitinib or pazopanib therapy and then nephrectomies were performed after 
approximately 3 months of treatment. Using TMAs constructed from this tissue 
we investigated important questions including the following: 
 
 Do VEGFR-TKI’s result in decreased vessel density? What is the degree of 
this reduction and does it correlate with patient outcome?  
 
 Are alternative (non-VEGF) pro-angiogenic factors up-regulated at the 
tumour site? Do either the baseline levels of pro-angiogenic factors or the 
degree of increase predict patient outcome? 
 
In the final section of this chapter we aim to address the lack of a representative 
preclinical model. We attempt to replicate published work in which the authors 
developed a preclinical model of ‘sunitinib resistance’. This preclinical model of 
resistance provides the backbone for the in vivo work included in the next two 
chapters. 
 
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 46 
3.3 Results 
 
3.3.1 Tissue origin and patient characteristics  
 
Human tissue used in this chapter derives from patients enrolled in 3 
independent single arm phase II studies with very similar inclusion criteri. Two 
of these trials used the VEGFR-TKI sunitinib (50mg PO OD – 4 weeks on 2 
weeks off) while the other trial used the VEGFR-TKI, pazopanib (800mg PO OD) 
72 73 74. 
 
Renal carcinoma was confirmed by biopsy prior to inclusion in the studies and 
these biopsies were later used for IHC analysis. Unlike standard of care, which 
involves nephrectomy prior to treatment onset, all 3 studies investigated the use 
of VEGFR-TKI therapy prior to planned nephrectomy. Nephrectomy was 
performed as soon as practicably possible after stopping VEGFR-TKI treatment.  
 
In total 98 patients were enrolled in these studies, but 36 patients were 
ineligible for analysis of matched tissue for various reasons; disease progression 
prior to planned surgery (n=20), co-morbidity (n=2), patient choice not to 
undergo surgery (n=9) and patients not recommencing VEGF TKI therapy within 
6 weeks (n=5). The primary analysis focuses on the prognostic significance of 
the observed changes to biomarkers on matched patient tissue i.e. tissue taken 
from the same patient pre- and post- treatment. 62 of the original 98 patients 
were eligible for this analysis. These patients restarted the same TKI therapy 
post nephrectomy with no evidence of progression of disease during pre-
nephrectomy systemic therapy. Patient characteristics for eligible patients are 
shown below. The author of this thesis played no role in measuring these clinical 
parameters. Author contribution was restricted to data collection and analysis.  
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 All patients Patients eligible for 
primary analysis 
 
Number of patients 
 
98 62 
Age 
 
59 (range: 37-78) 57 (range: 38-82) 
Gender 
male 
female 
 
75 
23 
 
45 
17 
MSKCC prognostic risk 
intermediate 
poor 
 
70 
28 
 
51 
11 
Number of metastatic sites 
1 
2   
3+ 
 
30 
39 
29 
 
25 
22 
15 
Treatment 
Pazopanib 
Sunitinib 
 
34 
64 
 
22 
40 
Reason for not having surgery 
and restarting TKI 
PD 
Patient choice 
Unfit for surgery 
No TKI post surgery 
Total  
 
 
20 
9 
2 
5 
36 
 
 
NA 
Platelet count 
 
300 (76-857) 294 (76-857) 
Neutrophil count 
 
5.8 (2.3-15.5) 5.35 (2.3-13.3) 
Best response to treatment 
PD 
SD 
PR/CR 
 
20 
62 
16 
 
0 
47 
15 
 T stage at nephrectomy 
T1 
T2 
T3 
T4 
 
NA 
 
 
 
9 
18 
29 
6 
PS at baseline 
0 
1 
2 
 
11 
67 
20 
 
8 
43 
11 
Clear cell grade at surgery 
1 
2 
3 
4 
NA 
 
NA 
 
 
3 
19 
31 
6 
3 
 
Table 3.1 Patient characteristics
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3.3.2 The effect of VEGFR-TKI treatment on vessel density 
VEGFR-TKIs are thought to act primarily through their impact of the tumour 
vasculature. To determine the impact of therapy on microvessel density (MVD), 
matched pairs of pre- (initial biopsies) and post-treated tumours 
(nephrectomies) were examined by IHC.  
Vessels were detected by IHC staining for CD31 protein. Vessel density (MVD), 
defined as total area stained positive for CD31 / total area of tissue core, was 
quantified using a computerised image analysis system (Ariol, Applied Imaging, 
Genetix) using visually-trained parameters. In patients where more than one 
scorable tissue core was available the mean score was calculated.  
In the matched patient samples MVD was significantly decreased with therapy 
(median fall 49.2%. p<0.01) [Figure 3.1]. Treatment reduced MVD in 35 out of 
41 patients where scorable tissue was available. The prognostic significance of 
the change in MVD was calculated using multivariate Cox regression analysis. 
Factors in the multivariate model included gender, grade, necrosis, MSKCC 
prognostic score, TKI treatment (sunitinib or pazopanib), initial response to TKI 
therapy, sites of disease. Individuals with a greater reduction in tumor 
vasculature (CD31 fall above median) had a better survival (HR3.07: 1.12-8.42 
p<0.05) [Figure 3.2].  
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Figure 3.1: The effect of VEGFR-TKI therapy on vessel density in human RCC 
samples. Panels (a) and (b) shows examples of CD31 staining in a highly vascular 
nephrectomy core and a nechrectomy core with low vessel density respectively. Panel 
(c) shows the impact on vessel density as measured by CD31 in patient-matched pairs 
(n=48). Vessels stained for CD31 were quantified using a computerised image analysis 
system (Ariol, Applied Imaging, Genetix) using visually-trained parameters. Microvessel 
density was defined as ‘area stained positive for CD31 / total tissue area’. Panel (d) 
shows CD31 scores from matched samples and also includes data from unmatched 
biopsies and nephrectomies (biopsies n=68, nephrectomies n=62). 
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Figure 3.2: The relationship between vessel density reduction and overall 
survival. This Kaplan Meier curve indicates that patients experiencing a great than the 
median fall in CD31 expression have a better prognosis. Survival was measured from 
the time of surgery (n=48). This Kaplan Meier curve was created in collaboration with a 
Barts Experimental Cancer Medicine Centre statistician. A statistical comparison was 
performed using the log-rank test. 
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3.3.3 The effect of VEGFR-TKI treatment on FGF-2 expression in 
matched patient samples  
 
The molecular mechanism underlying resistance to VEGFR-TKI therapy is not 
fully understood, but the resistance process is likely to be multi-factorial 75. It 
has been proposed that tumours can compensate by switching to non-VEGF pro-
angiogenic factors. The pro-angiogenic factor FGF-2 is anticipated to be a key 
player in this process. Several preclinical studies have highlighted the potential 
of FGF-2 to stimulate angiogenesis in this setting 67, 68 including a paper by Welti 
et al, in collaboration with our group, which demonstrated that the addition of 
FGF-2 can undermine sunitinib efficacy in an in vitro model of angiogenesis 69. 
To investigate the impact of FGF-2 on TKI-induced MVD reduction and patient 
outcome, TMAs were stained and scored for FGF-2 expression. FGF-2 was 
expressed in the nucleus and cytoplasm of tumour cells and, in some cases, 
vessels also stained positive for FGF-2 (examples are shown in Figure 3.3). 
Consequently, cores were scored separately for these three compartments. 31 
matched pairs of tissue were present and deemed scorable after the staining 
process.  This tissue was scored by both a trained pathologist [Rukma Doshi] 
and the author. For each core, scores for the nucleus and cytoplasm were 
generated by estimating the percent of tissue stained, which was multiplied by 
an estimate of the strength of staining (0 = negative, 1 = weak, 2 medium, 3 
strong). For vessels, cores were scored as positive if FGF-2 expression could be 
seen in one or more vessels. In cases where more than one core was present an 
average score was taken. 
In matched samples, there was no significant difference between the pre- and 
post-treatment levels of FGF-2 expression in either the vessels or the nuclear 
compartment of tumour cells. In the cytoplasmic compartment, expression of 
FGF-2 was significantly higher post-treatment [median rise 124%, p<0.01, see 
Figure 3.3 (d)]. Baseline levels FGF-2 expression did not correlate with patient 
outcome in any of the 3 tumour compartments. Furthermore, the degree of 
cytoplasmic FGF-2 increase was not associated with an increased risk of death 
(1.03; 95% CI 0.33-3.22, p=0.96). 
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Figure 3.3: Change in FGF-2 expression pre- and post- VEGFR-TKI therapy. 
Panels (a) and (b) shows examples of FGF2 staining in nephrectomy tissue with strong 
expression in the nuclear and cytoplasmic compartments respectively. Panel (c) and (d) 
shows the impact on FGF-2 expression pre- and post-treatment in patient-matched 
tissue (n=31).  
(c) Change in FGF2 nuclear staining   (d) Change in cytoplasmic staining  
 
 
(a) Example of tissue classified as 
negative for cytoplasmic FGF2, with 
strong and moderate and nuclear 
staining  
(b) Example of tissue classified as 
negative for nuclear FGF2, with 
strong cytoplasmic staining and FGF2 
positive vessels  
Pre-treatment Post-treatment
0
100
200
300
400
p = 0.59
pa
th
ol
og
ic
al
 s
co
re
Pre-treatment Post-treatment
0
100
200
300
P < 0.01
pa
th
ol
og
ic
al
 s
co
re
100 microns 100 microns
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 53 
 
3.3.4 The effect of VEGFR-TKI treatment on MET receptor in matched 
patient samples     
 
Further to FGF-2, the HGF/MET receptor pathway has been implicated as an 
alternative angiogenic pathway capable of promoting resistance to VEGFR-
TKIs69, 71. MET receptors expressed on endothelial cells are thought to be 
activated by ligand, Hepatocyte Growth Factor (HGF), which can be expressed 
by endothelial cells themselves, tumour cells or stromal cells such as fibroblasts.  
 
Further to angiogenesis, several preclinical studies show that VEGFR-TKIs can 
induce up-regulation of MET receptor in the tumour compartment, which may 
promote invasion and metastasis 70, 76. 
  
To investigate the impact of this signaling pathway on TKI-induced microvessel 
reduction and patient outcome, TMAs were stained and scored for MET receptor, 
scoring the tumour cells and vessels separately. 41 matched pairs of tissue were 
present and met quality control standards. These were scored by a trained 
pathologist [Colan Ho-Yen] and the author. For each core, scores for the tumour 
compartment were generated in a similar manner to FGF-2 (% of tumour 
positive multiplied by an estimate of the strength of staining; 0 = negative, 1 = 
weak, 2 medium, 3 strong). For vessels, the percent of MET receptor positive 
vessels was calculated with reference to another CD31-stained section, located 
in a tissue section adjacent to MET receptor-stained tissue. 
 
In the tumour compartment, there was no significant difference between the 
pre-treatment and post-treatment levels of MET receptor. However, treatment 
did induce a statistically significant increase in MET receptor in vessels. This 
increase in MET receptor did not predict patient outcome as measured by either 
overall survival or disease progression.  
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Figure 3.4: Change in MET receptor expression pre- and post- VEGFR-TKI 
therapy. Examples of MET positive vessels can be seen in panels (a) and (b) and panel 
(c) shows a tumour core with a tumour compartment classified as strongly positive. 
Panels (d) and (e) refers to the tumour compartment, whereas panels (f) and (g) shows 
the impact on MET receptor in tumour-associated vessels (n=41).  
(d) MET receptor tumour matched pairs (e) MET receptor tumour unmatched samples 
(f) MET receptor vessels matched pairs (g) MET receptor vessels unmatched samples 
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3.3.5 The effect of VEGFR-TKI treatment on Ki67 in matched and 
unmatched patient samples 
 
Ki67 is a nuclear protein expressed in cells in all active phases of the cell cycle, 
but absent in resting cells (G0). IHC of Ki67 is commonly used to establish the 
growth fraction of a tumour sample. A high Ki67 index has been associated with 
poor prognosis in multiple tumour types including renal cell carcinoma 77 78 79. 
Compared to FGF-2 and HGF/MET receptor there is comparatively little previous 
work looking at a link between Ki67 and VEGFR-TKI resistance, but there is 
some evidence that baseline levels of Ki67 index may be prognostic in patients 
treated with VEGFR-TKIs, albeit in a different tumour type 80. Consequently, 
TMAs were stained and scored for Ki67 expression. Scoring involved estimating 
the proportion of tumour cells that were Ki67-positive and this was performed 
by a trained pathologist [Dan Berney]. When there were multiple cores available 
to score for the same patient, the mean score was used. 
 
The Ki67 index increased post-treatment in both analyses [Fig 3.4]. However, 
restricting the analysis to matched patient samples, the increase did not reach 
statistical significance (median rise 26%, p=0.14). Furthermore, the level of 
increase during treatment was not associated with a significant increase in the 
risk of death [2.08 (95% CI; 0.68-1.46, p=0.13)]. Unlike previously published 
data in pancreatic neuroendocrine cancer, baseline levels of Ki67 were not 
predictive of patient outcome to VEGFR-TKI in this setting 80. It should be noted 
that Ki67 is an essential part of tool for the prognostic classification of 
pancreatic neuroendocrine cancer. Although some research has suggested that 
renal tumors with high Ki67 may predict for poor prognosis 77, this correlation 
does not appear to be as strong as in pancreatic neuroendocrine cancer. 
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Figure 3.5: Change in Ki67 index pre- and post- VEGFR-TKI therapy. Panel (a) 
uses the mean score per patient when multiple cores are available and restricts analysis 
to patients for which matches tissue was scorable (n=38). Panel (b) also uses the mean 
score per patient but incorporates unmatched biopsies and nephrectomies (biopsies 
n=61, nephrectomies n=59).  
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3.3.6 Heterogeneity 
 
Phenotypic and functional heterogeneity arise among cancer cells. This 
heterogeneity can influence therapy outcome, particularly when the target of 
molecular therapy is inconsistently expressed on tumour cells. Furthermore, 
heterogeneity can adversely affect biomarker analysis if sample bias confuses 
biomarker identification.     
 
Multiple samples were taken from within the same treated tumors to investigate 
heterogeneity of tumour biomarker expression (n= 5). Significant intra-tumour 
heterogeneity was observed for all biomarkers investigated (Figure 3.6). Further 
analysis using array CGH and DNA methylation analysis (MethylCap-seq) 
showed the observed variability seen at the protein level was largely driven by 
genetic rather than epigenetic instability. This work was carried out in 
conjunction with external collaborators and does not form part of this thesis 
(data not shown).  
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Figure 3.6: Examples of intra-tumour heterogeneity in treated samples. IHC 
scores for CD31, Ki67, CD45 and FGF-2 are shown from patients with at least five cores 
available from different tumor regions taken after treatment. 
 
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 59 
 
 
3.3.7 Developing a preclinical model of ‘sunitinib resistance’ 
 
Clinical experience suggests that while most RCC patients benefit from VEGFR-
TKI treatment, tumours inevitably acquire a resistant phenotype. In a recent 
paper, Huang et al 39 showed that xenografts were capable of replicating the 
clinical experience. That is to say, tumours in xenografts that were continuously 
treated with sunitinib were initially well controlled by treatment but then 
appeared to develop a resistant phenotype as tumour growth returned.  
 
We attempted to replicate the published models in order to further investigate 
which factors help promote the resistance process. The development of a 
sunitinib-resistant preclinical model was partly motivated by the desire to 
challenge resistant tumours with a SRC inhibitor, which we hypothesised may be 
effective in this setting.  
 
Following the protocol outlined with by Huang et al 39 786-O xenografts were 
established in 6-8 week old female SCID mice by s.c. injection of 5 × 106 cells 
into the animal’s flank. 30 days post inoculation, when tumours were 
measurable and growing consistently (tumour volumes 0.3-0.8 cm3) mice were 
treated with 40mg/kg sunitinib once daily by oral gavage. As seen in the 
previously published work 39,  tumours initially regressed before rebounding 
[Figure 3.7 (d)]. Minimum measurements were recorded between Day 17 and 
Day 28. The degree of treatment-induced tumour regression correlated with the 
size of the tumour prior to treatment onset [Figure 3.7 (e)]. 
 
In contrast A498 xenografts, also continuously treated with sunitinib (40mg/kg 
O.D), benefitted from strong tumour regression upon treatment onset, but 
showed no signs of rebound after sustained treatment for over 40 days. 
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Figure 3.7:  Investigating 3 different RCC xenografts as potential models for 
VEGFR-TKI resistance. Panel (a) is an example of a vehicle treated ACHN tumour 45 
days post inoculation. Sections were IHC stained for CD31. Panel (b) shows an example 
of a CD31-stained vehicle treated 786-O xenograft. Panel (c) shows the effect of 
sunitinib (40mg/kg O.D) treatment on tumour volume in 6 mice harbouring A498 
xenografts. Panel (d) shows the effect of the same treatment regimen on 15 mice 
harbouring 786-O tumours. Panel (e) represents the same mice, but only the first and 
last measures smallest are shown. Panel (f) shows the positive correlation between the 
size of tumour prior to treatment onset and the subsequent drug-induced tumour 
shrinkage (calculated as the difference between the first measure and the smallest 
measure). 
(c) A498 xenograft treated continuously with sunitinib  (d) 786-O xenograft treated continuously with sunitinib 
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3.4 Discussion 
 
Preclinical models have shown that VEGFR-targeted therapy can affect vessel 
function, permeability and induce normalisation 81. Furthermore, preclinical 
studies invariably show that TKIs are capable of reducing MVD in these models. 
Typically, these preclinical models involve fast-growing tumours set within the 
highly vascular subcutaneous microenvironment and so its not clear how 
representative these models are of the clinical setting 81. Furthermore, the value 
of MVD as a pharmacodynamic marker of anti-angiogenic drug efficacy has been 
questioned since, over a period of time, vessel reduction may be expected to 
result in a similar reduction in viable tumour mass leaving the intercapillary 
distance largely unchanged 82. 
 
Very few clinical studies have been designed in a way that allows the direct 
measurement of treatment-induced MVD reduction. When this has been 
possible, a significant decrease in MVD has not always been observed 83. 
Moreover, when a decrease is observed, the studies have been underpowered to 
investigate the impact on patient outcome 84.  
 
The design of 3 recently completed clinical trials gave us access to biopsy tissue 
taken before any treatment and patient tissue taken from the same patients 3 
months after VEGFR-TKI treatment onset. This allowed us to examine the 
degree of MVD reduction in RCC patients for the first time. Since matched tissue 
was available in the majority of these patients we had the opportunity to assess 
the correlation between MVD reduction and patient outcome. A greater than 
average reduction in vessel density was associated with increased overall 
survival. To our knowledge, this is the first study to demonstrate a direct 
correlation between reduced vessel density and patient outcome in the clinical 
setting.  
 
In addition to examining the degree of vessel density reduction, we also 
investigated whether the absolute levels (both pre-treatment and post-
treatment) correlated with patient outcome. In both cases, absolute vessel 
density did not correlate with overall survival.  
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The pro-angiogenic potential of FGF-2 is long established 85. In more recent 
times, FGF-2 has been proposed as a key mediator of drug-resistance in mRCC 
69 37. Increased circulating concentrations of FGF-2 have been reported in 
patients progressing on VEGF-targeted therapy 86. Because FGF-2 exerts a 
paracrine effect to promote angiogenesis 87, the level of FGF-2 at the tumour 
site, rather than the level of FGF-2 in the circulating pool, would seem to be the 
more relevant measurement.  
 
FGF-2 expression can occur in both the cytoplasmic and nuclear compartments. 
Furthermore, the subcellular location is thought to play a role on the function of 
FGF-2 88. Consequently, tissue was scored for nuclear and cytoplasmic FGF-2 
separately. Nuclear FGF-2 was unaffected, but VEGFR-TKI therapy increased 
expression of cytoplasmic FGF-2 expression at the tumour site. However, we 
found no significant correlation between the degree of FGF-2 up-regulation and 
patient survival. Furthermore, FGF-2 expression levels (both pre- and post-
treatment) did not correlate with patient outcome.  
 
Other clinical studies have collected on-treatment patient blood samples to 
investigate circulating factors that may contribute to resistance 89. Our approach 
to look at pre- and post-treatment tissue samples has both benefits and 
limitations. One clear advantage is the ability to look at tumour expression in 
situ. This is potentially important in view of recent evidence that TKI treatment 
can induce a systemic up-regulation of pro-angiogenic factors, which occurs in a 
tumour-independent manner 35. Blood sample measurements incorporate both 
tumour-derived and systemic expression of these factors, confusing any 
analysis. Our approach confirms that there was a significant increase in the pro-
angiogenic ligand FGF-2 and this occurred in the tumour compartment in direct 
proximity to the target vessels.  
 
However, the non-invasive nature of blood sample collection allows multiple 
samples to be taken which can be compared to tumour response on a dynamic 
basis. For example, FGF-2 was shown to increase in the blood of TKI-treated 
glioblastoma patients at the time of progression 90. In this study, we analysed 
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 63 
FGF-2 expression at one post-treatment timepoint - three months into therapy. 
At this stage, as a requirement to perform the nephrectomy, none of the 
patients contributing to the matched tissue pairs had progressed. Consequently, 
what our analysis does show is that mRCC tumours can up-regulate FGF-2 in 
response to VEGF-targeted therapy. This occurred in patient still responding to 
treatment. The extent to which FGF-2 expression contributes resistance is not 
clear from our study.  
Preclinical studies suggest VEGFR-TKI therapy can up-regulate expression of 
MET receptor in tumor cells, potentially promoting tumor invasion and 
metastasis 70, 76. In this study we found no evidence for up-regulation of MET 
receptor at the tumour site. However, we did see up-regulation of MET receptor 
in tumour-associated vessels. Up-regulation of MET receptor in the vascular 
compartment could provide an alternative pro-angiogenic signal for endothelial 
cells in the presence of its ligand, hepatocyte growth factor (HGF). Previous 
work suggests that HGF may also be up-regulated in response to VEGFR-TKI 
which could work synergistically with MET receptor up-regulation 71. In the 
absence of a suitable antibody, it was not possible to investigate whether HGF 
expression was effected by treatment in the TMA. Moreover, despite efforts to 
obtain an antibody that measured levels of phosphorylated MET receptor we 
could not find an antibody that passed our quality control in terms of 
demonstrating specific binding to the target. As a result we were not able to 
measure MET receptor activation in addition to total MET receptor levels. 
 
Ki-67 is a measure of tumour proliferation and provides an independent marker 
of tumour aggressiveness in several cancer types, including renal carcinoma 77 78 
79. This marker was chosen to test the hypothesis that these drugs have an 
effect on tumour cellular proliferation, potentially leading to a more aggressive 
tumour phenotype. VEGF TKI treatment may result in dynamic changes at the 
molecular level that lead to a more resistant, aggressive tumour phenotype. 
While a significant increase in Ki67 was seen when taking into account all 
samples (including unpaired samples [Figure 3.5 (b)]) the primary focus of our 
analysis is the matched tissue samples. In this tissue a statistically significant 
change in Ki67 was not observed [Figure 3.5 (a)].  
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Molecular heterogeneity is challenging because sampling bias may prevent 
detection of biologically significant changes in biomarker expression. Intra-
tumor heterogeneity can occur at the genetic level, but can also be impacted by 
epigenetics and regional differences in the tumor microenvironment. 
Investigating biomarkers at the protein level, rather than at the DNA level, can 
be particulary problematic because protein expression can be affected by all 
three of the above variables i.e. protein expression can be altered by the 
underlying genotype, epigenetics and the local microenvironment. 
 
Heterogeneous protein expression can be particularly unhelpful when dealing 
with small biopsies that may not necessarily reflect the pattern of biomarker 
expression in the tumors that they represent. One potential strategy to mitigate 
the effect of tumor heterogeneity is to use multiple tissue samples from the 
same patient. Where possible we employed this strategy in our biomarker 
analysis.  
 
Analysis of multiple samples taken from different regions within the same 
tumour indicated significant intra-tumour heterogeneity in our RCC tumour 
sample set, supporting previous results in this tumour type 91. Despite this 
heterogeneity, we still observed significant changes in several key biomarkers, 
including CD31, MET receptor and FGF2. Arguably, the ability to detect 
significant changes in these biomarkers across a sample that is intrinsically 
heterogeneous, acts to further reinforce the significance of these changes.    
 
There are several shortcomings to this work. The tissue originated from three 
different studies, although these studies were very similar in design. A decision 
was made to concentrate on matched tumour samples. While this allowed a 
direct comparison of pre- and post-treatment tissue, it potentially biased the 
sample set. Not all patients were able to have sequential tissue taken due to 
lack of excess tissue for sampling and patients coming off study.  The tissue 
samples allowed us to investigate biomarker changes that occurred in 
conjunction with treatment in the presence of vessel density reduction. 
However, without time-matched controls it is possible that the observed 
increases in FGF-2, MET receptor and Ki67 are simply indicative of normal 
disease progression.  
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Efforts to understand resistance have been hampered by the lack of 
representative preclinical models. Moreover, the lack of suitable preclinical 
models has hampered drug development efforts to counteract the onset of 
acquired resistance. To investigate the potential efficacy of SRC inhibitors in 
anti-VEGF resistance a preclinical model of sunitinib resistance was developed. 
Initial attempts to develop a model based on the ACHN cell line were 
unsuccessful. Vehicle treated tumours were observed to have large necrotic 
centres surrounded by a limited amount of viable tumour. ACHN cells are VHL 
wild-type and so may not express as much VEGF ligand as xenografts based on 
VHL mutated cell lines such as A498 or 786-O. In line with this hypothesis, IHC 
staining for the vessel marker CD31 shows that ACHN had relatively low vessel 
density [Figure 3.7 (a) and (b)]. 
 
A498 tumours grew more successfully and responded well to sunitinib 
treatment. Unfortunately we could not generate a ‘resistant model’ because we 
failed to observe tumour re-growth [Figure 3.7 (c)]. 
 
In line with previously published work by Huang et al 39, all 15 786-O xenograft 
tumours initially responded to treatment leading to tumour regression. 
Furthermore, in 15 out of 15 tumours, re-growth in excess of 20% was observed 
in response to sustained sunitinib treatment. In the clinical setting a growth in 
excess of 20% would meet the threshold required to be classified as ‘progressive 
disease’ under RECIST criteria 33. In contrast, Huang et al found that 3 out of 18 
tumours failed to re-grow. These tumours were not considered to be resistant to 
sunitinib. In fact, the molecular profile of these 3 ‘sensitive’ tumours were 
compared to the ‘resistant’ tumours to look for drivers of resistance. In their 
publication, Huang et al do not show growth trajectories prior to sunitinib 
treatment. Nor do they confirm that tumours were measured over time prior to 
treatment to increase confidence that any tumour regression observed could be 
attributed to treatment. In our protocol, to be included in the study, tumours 
needed to demonstrate consistent growth at 3 consecutive time-points prior to 
treatment onset. In this way, we hoped to avoid including tumours that simply 
did not ‘take’ properly. Tumours that don’t ‘take’ properly may have a growth 
profile that could be confused with a sustained response to sunitinib i.e. tumours 
that fail to develop resistance. 
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This 786-O xenograft model forms the primary focus of the in vivo work 
contained in the next two chapters of this thesis. In Chapter 4 we use this model 
to investigate the use of SRC inhibitors to overcome resistance. In Chapter 5 we 
investigate what was driving resistance in the 786-O model and revert back to 
the RCC patient tissue samples to verify whether a similar process could be 
observed in the clinic. 
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Chapter 4: 
Investigating the potential of SRC-TKIs in Renal 
Cell Carcinoma therapy 
 
4.1 Introduction 
  
Anti-angiogenic therapy has revolutionised the treatment of metastatic renal cell 
carcinoma (RCC). But while VEGFR-TKIs provide a significant clinical benefit, 
responsive patients inevitably relapse. A number of ‘acquired resistance’ 
mechanisms have been proposed, most prominently; (1) a renewed capability to 
induce angiogenesis and (2) the promotion of metastasis. SRC in best known for 
its role in the focal adhesion complex, a pathway is thought to play a central 
role in cell motility, adhesion and the metastatic process. In addition, published 
data, albeit in non-RCC tumour models, suggests that SRC kinase can regulate 
pathways involved in angiogenesis. Consequently the addition of a SRC kinase 
inhibitor to VEGFR-TKI therapy may provide a rational combination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: SRC is thought to be central to a number of pathways involved in metastasis 
and angiogenesis. 
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4.2 Aims of chapter 
 
The work presented in this chapter investigates the effect of the SRC kinase 
inhibitors saracatinib and dasatinib in various preclinical models. The ultimate 
goal was to establish whether the addition of SRC kinase inhibitors to VEGFR-
TKI therapy could provide a rational combination, but SRC kinase inhibition as 
monotherapy was also investigated. Treatment effect on cell viability and 
migration was investigated in vitro, before moving into the 786-O xenograft 
model. Using this xenograft model the effect of SRC inhibition on apoptosis, 
proliferation and angiogenesis were investigated. Furthermore, the effect on 
gene expression was analysed in an effort to better understand the mechanism 
of action on the observed anti-tumour effect. 
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4.3 Results 
 
4.3.1 Cell line selection for functional assays 
 
Prior to undertaking functional studies, a panel of 12 cell lines was characterized 
for SRC expression and activity levels. Auto-phosphorylation of residue Y419, 
located in the kinase domain, is required for full activity and has been proposed 
as a biomarker for SRC-TKI efficacy 92. Conversely, SRC can be negatively 
regulated by phosphorylation at residue Y530, which causes the protein to lock 
into a closed structure with the kinase domain inaccessible 93. 
 
Cell lysates from the cell line panel were probed for total SRC protein, SRC 
phosphorylated at residue Y419 and SRC phosphorylated at Y530. All cell lines 
expressed SRC protein, but there was a significant difference in the 
phosphorylation status of the different cell lines. Four well-characterised cell 
lines were chosen for future functional studies, A498, ACHN, 786-O and Caki-1. 
As figure 4.1 (a) shows these cell lines had quite different phosphorylation 
profiles with the ACHN cell line having very little SRC protein phosphorylated at 
the Y530 site, which renders the protein inaccessible and inactive. Whereas the 
A498 cell line showed a comparatively high proportion of protein phosphorylated 
at Y530 and less auto-phosphorylation of the Y419 residue. 
 
 
4.3.2 The effect of dasatinib on SRC kinase activity 
 
Initial in vitro functional studies were conducted using the commercially 
available SRC TKI, dasatinib (cell viability assays were repeated using the SRC 
inhibitor saracatinib, which was donated by AstraZeneca, prior to conducting any 
xenograft studies). Dasatinib is an orally active small molecule shown to be a 
dual SRC / Abl TKI62. The drug was developed, primarily, as a second line 
treatment for the treatment of chronic myelogenous leukemia (CML) 59. CML is 
associated with the t(9;22) chromosomal translocation, which generates the 
oncogenic BCR-ABL fusion gene. More recently, the potential of dasatinib to 
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inhibit metastasis has been investigated through its inhibition of SRC kinase 94. 
We confirmed dasatinib’s ability to inhibit SRC kinase activity in our panel of 4 
RCC cell lines before proceeding with functional assays. Figure 4.1 (b) indicates 
that dasatinib reduced phosphorylation of the Y419 residue, in a dose-
dependent manner. Compared to the other cell lines, dasatinib seemed more 
capable of reducing SRC activity of the ACHN cell line at the lowest dose level 
investigated (10 nm).    
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Figure 4.2: Characterisation of SRC protein levels and phosphorylation status in a panel 
of 12 RCC cell lines and the effect of dasatinib on SRC activity on 4 cell lines chosen for 
functional assays. Panel (a) shows the result of 12 cell lines probed for total SRC and 
phosphorylated SRC-Y419 by western blot. The cells probed were (1) ACHN (2) CAKI-1 (3) CAKI-2 
(4) CAL54 (5) A498 (6) 786-O, 769-P, RCC6, RCC7, RCC12, RCC38 and RCC42. Panel (b) 
demonstrates the effect of dasatinib on the SRC kinase activity on 4 cell lines chosen for functional 
assays. Lysates were harvested 6 hours after adding (1) 0nM (2) 10nM (3) 50nM or (4) 250nM of 
dasatinib.  
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4.3.3 The effect of dasatinib on cell viability 
To determine the effect of dasatinib on cell viability an MTS assay was 
performed treating cells for both 24 and 72 hours. Figure 4.3 (a) shows the 
impact of dasatinib on cell viability after 72 hours of dasatinib treatment. A498 
appeared the most resistant to treatment with ACHN the most sensitive cell line 
[Figure 4.3 (a)]. A similar pattern was seen at 24 hours (data not shown). 
 
Cell viability assays were also carried out using an alternative SRC inhibitor, 
saracatinib. Again, a similar pattern was seen with A498 was the most resistant 
to treatment, followed by 786-O with the drug having the most impact on ACHN 
cell viability (data not shown). 
It was noted that the two VHL -/- cell lines A498 and 786-O were the most 
resistant cell lines. Given the high prevalence of VHL mutation in RCC, further 
experiments were conducted to determine whether the loss of functional VHL 
could promote resistance to SRC inhibitors. 
We hypothesised that if VHL mutation was conferring resistance, it may be 
through reduced degradation the HIF (hypoxia-inducible factor) transcription 
factors. Therefore, by stablising HIF transcription factors in VHL wild-type cells 
we hypothesized resistance would occur. Efforts were made to stablilise HIF both 
with the use of a hypoxia incubator (oxygen was set to 1%) and with a 
pharmacological agent (dimethyloxalylglycine). Western blots showed successful 
stabilisation by these methods, but the lack of oxygen and treatment effects 
resulted in a significant loss in cell viability making it impossible to test whether 
HIF stabilisation promoted resistance (data not shown). 
Consequently we used the RCC4 VHL +/- isogenic cell line to test our 
hypothesis. We compared the effect of dasatinib treatment on stably transfected 
RCC4 cell lines expressing vector alone (RCC4) or wild-type VHL (RCC4 + VHL-
WT). As shown in Figure 4.3 (b), VHL loss did promote resistance to dasatinib 
confirming out hypothesis. 
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Figure 4.3: The effect of dasatinib on cell viability. Panel (a) compares the treatment effect 
on four cell lines. Panel (b) demonstrates that VHL loss promotes resistance in the isogenic 
VHL+/- RCC4  cell line. In both experiments, cells were seeded at 3-6 x 103 cells per well on 96-
well plates and cultured in 100ul of RPMI-media overnight. The following day, 100ul of dasatinib 
was added to achieve a range of final concentration between 0uM and 1uM. Cell viability was 
determined at 72 hours following the manufacturer’s protocol (MTS assay, Promega). 
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4.3.4 The effect of dasatinib of cell motility and migration 
 
SRC inhibitors have demonstrated the ability to reduce cell motility using cell 
lines originating from several different tumour types. To confirm that SRC 
inhibitors could reduce motility of RCC cells in vitro, all four cell lines were 
plated into 6 well plates and incubated until cells were more than 90% confluent 
(24-48 hours). A scratch was made in each well and an image taken. Media was 
replaced with media containing 10nM, 50nM, 250nM of dasatinib. A well with no 
dasatinib added was used as a control. Assays were performed in triplicate. After 
18 hours incubation a further image was taken and the distance between the 
cells where the original scratch took place was observed. In all 4 cell lines a 
visible difference in the migration rate could be seen at the 10nM dose level 
when compared to control wells. A representative image showing the effect on 
50nM can be seen below. Similar experiments were performed with the SRC 
inhibitor saracatinib generating similar results (data no shown). 
To better quantify the effect of SRC inhibition on migration, transwell migration 
assays were performed. Media containing 5% serum was used as the chemo-
attractant agent. As figure 4.4(b) shows, dasatinib reduced cell migration in a 
dose-dependent manner in all RCC cell lines tested. The reduction in migrated 
cells reached statistical significance (p<0.01) at 50nM and above in all cell lines, 
but only ACHN reached statistical significance at the 10nM dose level. 
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Figure 4.4: The effect of dasatinib cell migration. Panel (a) shows a representative 
image of a scratch assay. 7.5 x 104 cells per well were plated and incubated for 24-48 hours until 
cells were confluent. A cross was scratched into the monolayer using a 1ml pipette tip, cell washed 
in PBS and media replaced with containing 50nM dasatinib or 0nM dasatinib (control). A further 
image was taken 18 hours later to measure dynamic changes in cell migration. Panel (b) shows 
the results of transwell assays (n=3) performed on the four cell lines. Briefly, 2.5 x 105 cells per 
added to each transwell and incubated for 3 hours to allow cells to adhere to the transwell 
membrane. Media was removed before 200ul of serum-free media containing 0-250ul of dasatinib 
was added to the upper chamber of the transwell. The lower chamber contained, 500ul of media, 
containing the same concentration of dasatinib as the upper chamber, with the addition of 5% 
fetal calf serum. Cells were allowed to migrate towards serum for 18 hours before being, fixed, 
stained with haematoxylin and counted.  
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4.3.5 Saracatinib effects biomarkers of the focal adhesion complex 
and phospho-STAT3 in the 786-O xenograft model 
 
The 786-O model was used to investigate the effect of SRC inhibitors on 
pharmacodynamic biomarkers in vivo. For this purpose, a short-term chronic 
dose study (once-daily dosing for 4 days) was conducted. SRC inhibitor 
monotherapy (saracatinib) and its combination with the VEGFR-TKI cediranib 
was investigated.  
 
786-O xenografts were established in the flank of SCID mice into one of 4 
groups; vehicle, saracatinib monotherapy, cediranib monotherapy or the 
combination of saracatinib and cediranib (n = 7 for the vehicle group and n= 5 
for all other treatment groups). Tissue was harvested 3 hours after the final 
dose. 
 
At 25mg/kg, saracatinib visibly reduced the phosphorylation of FAK and paxillin, 
both key players in the focal adhesion complex and known downstream targets 
of SRC [Figure 4.1 (a)-(b)].  
 
Phospho-STAT3 is also thought to be regulated by SRC and through this 
interaction regulate the expression of VEGF 95. Saracatinib significantly down-
regulated phospho-STAT3 (p<0.01 [Figure 4.5 (c)] Although sunitinib has been 
suggested to reduce STAT3 phosphorylation 96 65, we could find no evidence of 
this [Figure 4.5 (c)]. 
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Figure 4.5: The effect of saractinib on pharmacodynamic biomarkers. Panel (a) and (b) are 
representative examples of the effect of SRC inhibition on the activity of the focal adhesion 
complex proteins FAK and paxillin respectively. Panel (c) shows an example of phospho-STAT3 
IHC staining and the resulting quantification using image analysis software. Saracatinib 
significantly down-regulated phospho-STAT3 (p<0.01).  
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4.3.6 Saracatinib decreases VEGF gene expression but this does not 
affect vessel density 
 
SRC is thought to regulate VEGF ligand expression through its interaction with 
STAT3 95. We hypothesized that by reducing STAT3 activity [Figure 4.5 (c)] SRC 
inhibitors could decrease VEGF expression and so reduce vessel density. 
 
In line with our hypothesis, Figure 4.6 (a) shows that VEGF-A gene expression 
was significantly reduced, both in the tumour and host compartments. However, 
this did not translate into a significant change in vessel density [Figure 4.6 (c)]. 
 
In addition to saracatinib monotherapy, the effect of saracatinib / cediranib 
(VEGFR-TKI) combination therapy was investigated. Cediranib monotherapy 
significantly increased the expression of VEGF and MMP2 in the host [Figure 4.6 
(b)]. As suggested by previous studies, saracatinib monotherapy significantly 
reduced the expression of both genes, further supporting our hypothesis that 
the addition of a SRC inhibitor to anti-angiogenic therapy may provide a rational 
combination. However, when combined with cediranib, rather than reducing 
gene expression (compared to cediranib monotherapy) saracatinib exacerbated 
the up-regulation (p<0.01). 
 
Staining for CD31 revealed that there was a trend in favour of reduced vessel 
density in the combination arm but this did not reach statistical significance 
[Figure 4.6 (c)]. 
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Figure 4.6: The effect of saracatinib on VEGF expression and vessel density: Panel (a) 
shows the effect of saracatinib on VEGF expression. Panel (b) shows the effect of saracatinib 
monotherapy and combination therapy on gene expression and panel (c) shows treatment effect 
on vessel density (measured at Day 4). 
p < 0.01 p < 0.01 
p < 0.01 p < 0.01 
(a) Effect of saracatinib treatment on VEGF expression   
(b) Effect of saracatinib monotherapy and combination therapy on gene expression  
(c) Effect of saracatinib monotherapy and combination therapy on vessel density  
p < 0.01 
p < 0.01 
200 microns
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4.3.7 The effect of saracatinib treatment on cell viability and 
proliferation in vivo 
 
To test whether saracatinib monotherapy, or its combination with cediranib 
effected cell viability or proliferation, treated tissue (4 days) was stained for 
cleaved caspase 3 and Ki67 and compared with controls. 
 
Neither saracatinib, cediranib nor the combination had any effect on Ki67 levels, 
indicating no treatment effect on proliferation [Figure 4.7 (a)].  
 
Saracatinib monotherapy did not have a significant effect on cleaved caspase 3 
expression indicating treatment had no effect on the proportion of apoptotic cells 
[Figure 4.7 (b)].  Staining indicated that cediranib did significantly increase the 
proportion of apoptotic cells (p<0.01). The addition of saracatinib to cediranib 
further increased the proportion of apoptotic cells, but the increase did not reach 
statistical significance. 
 
Although the effect didn’t reach statistical significance, the trend in favour of 
increased apoptosis in the combination, together with previous data showing 
that saracatinib could decrease STAT3 activity [Figure 4.5 (c)] led us to further 
investigate a potential synergistic mechanism of action for the combination 
therapy. STAT3 is thought to regulate the expression of the several anti-
apoptotic genes including BCL-XL and BCL-2. We hypothesised that if saracatinib 
was down-regulating these anti-apoptotic genes, it could increase the ability of 
cediranib to induce the apoptosis seen in the monotherapy. PCR was conducted 
to look for evidence of this potential mechanism of action. We found no 
significant change in the level of BCL-XL or BCL-2 expression level in treated 
tumours (data not shown). 
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Figure 4.7: The effect of saracatinib on cell viability and proliferation in 786-O 
xenografts: Tissue taken after 4 days of treatment was stained for Ki67 (panel a) and cleaved 
caspase 3 (panel b) to investigate the effect on proliferation and apoptosis respectively. 
(a) Effect of saracatinib treatment on proliferation   
(b) Effect of saracatinib treatment on apoptosis   
200 microns
200 microns
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4.3.8 Saracatinib reduces tumour growth both as monotherapy and 
in combination with the VEGFR-TKI cediranib 
 
To investigate the effect of the respective monotherapies and combination 
treatment on tumour growth, mice were inoculated with 786-O cells and 
tumours measured twice weekly with calipers until they reached palpable size. 
To qualify for the study, tumours needed to have recorded volume growth on 
both of the two prior measurement days before randomisation.   
 
Animals were randomised into one of 4 treatment groups (n = 12); the SRC 
inhibitor saracatinib at 25 mg/kg, the novel anti-VEGF cediranib at 3mg/kg, a 
combination of the two drugs (25mg/kg + 3mg/kg) or vehicle. Randomisation 
date occurred on day 30 – at that stage tumour volumes ranged from 0.2-0.8 
cm3. All drugs and vehicle were administered once daily by oral gavage. The 
effect on tumour growth can be seen in Figure 4.8 (a). 
 
All therapeutic arms significantly slowed tumour growth versus vehicle 
(saracatinib p < 0.05, cediranib and the combination p < 0.01). Furthermore 
combination therapy achieved tumour regression, as opposed to just slowing 
tumour growth. Combination therapy was significantly more effective than either 
monotherapy (p < 0.01). 
 
We were most interested in investigating the potential benefits of SRC inhibitors 
in tumours that had acquired a ‘resistant’ phenotype. As shown previously 
[Figure 3.7], in our hands 100% of sunitinib-treated 786-O xenografts 
demonstrated a growth rebound after initial regression. 30 mice were treated 
with 40 mg/kg sunitinib for 22 days. Mice were randomised into one of two arms 
at Day 22; (1) cediranib at 3mg/kg or (2) cediranib plus saracatinib at (3mg/kg 
+ 25mg/kg). Again combination treatment was more effective than cediranib 
monotherapy (p < 0.01). In contrast to treatment naïve xenografts, combination 
therapy was not able to induce tumour regression in tumours pre-treated with 
sunitinib.  
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Figure 4.8: The anti-tumour effect of saracatinib monotherapy and in combination with 
the anti-VEGF drug cediranib: Panel (a) shows the effect of therapy in treatment naïve 
xenografts. Animals received saracatinib 25 mg/kg, cediranib 3mg/kg a combination of the two 
drugs (25mg/kg + 3mg/kg) or vehicle once daily by oral gavage (n=12). Tumour volumes 
represent the geometric mean of the treatment group (n=12). Error bars represent SEM. Panel (b) 
shows the effect of different therapy in xenografts pre-treated with 40 mg/kg sunitinib for 22 
days. Animals were then treated with cediranib 3mg/kg a combination of saracatinib and cediranib 
(25mg/kg + 3mg/kg) by oral gavage (n=15). 
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4.4 Discussion 
 
SRC has been shown to regulate a number of pathways involved in 
tumourgenesis 54. SRC protein expression and activity has been shown to 
correlate with progression and site-specific metastasis in several different 
tumour types 97 98 55 99. SRC inhibition has been shown to reduce cell motility 
and growth in multiple disease-specific preclinical models 100 101 102. 
Furthermore, SRC inhibitors have been shown to act synergistically with other 
treatment modalities 103 104. A ‘test panel’ of 4 cells lines was selected to 
investigate the effect of SRC inhibitors in preclinical models of RCC both as a 
monotherapy and as combination therapy in conjunction with anti-VEGF 
treatment.  
 
MTS assays demonstrated that the SRC inhibitors dasatinib [Figure 4.3 (a)] and 
saracatinib (data not shown) affected RCC cell viability. The size of this effect 
varied greatly between the different cell lines. Previous work highlights the 
potential of VHL mutation to promote drug resistance through either the NF-Kβ 
or HIF-alpha pathway 105 106. Based on the observation that treatment effect 
correlated with VHL status in the four cell lines tested, we hypothesized that VHL 
loss was promoting resistance to SRC TKI treatment.  
 
Initial studies to investigate this hypothesis used either a hypoxic incubator or 
small molecule HIF-stabilising agents to stabilize HIF in VHL wild-type cells (data 
not shown). Interpreting the results of these studies was confounded by the 
effect of hypoxic conditions (or stabilizing agents) on cell growth. However, the 
use of the RCC4 VHL+ / VHL- isogenic cell lines demonstrated that VHL was 
promoting resistance to dasatinib [Figure 4.3 (b)] and saracatinib (data not 
shown). This result has subsequently been corroborated by another group using 
two different VHL+/ VHL- isogenic cell lines of RCC origin, ACHN and SN12C 107. 
 
Transwell migration assays and scratch assays confirmed the ability of SRC 
inhibitors to reduce the motility and migration of all RCC cell lines tested [Figure 
4.4]. This effect was observed in all cell lines at a dose level (10nm) that 
precluded any treatment effect on cell viability being the primary driver for the 
observed decrease in cell migration. Metastasis has been proposed as a key 
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mechanism of resistance to anti-VEGF treatment 40 41. The confirmation that SRC 
inhibitors decrease migration of RCC cell lines highlights the potential for a 
potential synergistic combination with anti-VEGF treatment.  
 
A major limitation of our work is that we did not test the potential benefit of SRC 
inhibition in a preclinical model of anti-VEGF-induced metastasis. Instead, we 
focused our animal studies a resistance model characterized by growth rebound 
of the primary tumour. 
 
By replicating previous work by Huang et al 39 we developed a preclinical model 
of sunitinib resistance [Figure 3.7]. In their paper Huang et al described a model 
of renewed angiogenesis driven by up-regulation of IL-8. SRC has been 
implicated as a key mediator of IL-8 expression in a number of cell lines 
suggesting SRC inhibition may impact this resistance mechanism in the 786-O 
model 108 60 109. In addition, SRC has been implicated in the regulation of VEGF 
expression 110 111 95. Finally, recent work has suggested that SRC inhibitors can 
directly affect migration and survival of endothelial cells thereby reducing 
angiogenesis 58. Taken together, these results suggest the addition of a SRC 
inhibitor to anti-VEGF therapy may delay or prevent renewed angiogenesis in 
the 786-O preclinical model.  
 
Saracatinib was able to significantly reduce phospho-STAT3 levels in the 786-O 
xenograft [Figure 4.5 (c)]. Moreover, saracatinib treatment reduced VEGF gene 
expression in both the tumour and host compartments [Figure 4.6 (a)]. 
However, the observed VEGF reduction did not translate into a significant 
reduction in vessel density when compared to time-matched controls [Figure 4.6 
(c)]. Another key limitation to our work is the reliance on one timepoint (tissue 
was taken 3 hours after the Day 4 dose) to analyze vessel density, gene 
expression and other biomarkers by IHC. VEGF gene expression investigated 3 
hours after dosing may not be reflective of the treatment effect over the course 
of treatment. 
 
The anti-VEGF drug cediranib was used to investigate the potential synergy of 
adding a SRC inhibitor to anti-angiogenic therapy. The addition of saracatinib to 
the anti-VEGF drug cediranib failed to significantly reduce vessel density beyond 
that observed with cediranib monotherapy [Figure 4.6 (c)]. It should be noted 
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that cediranib monotherapy reduced vessel density by approximately 90% which 
arguably left little scope for a further improvement in vessel density reduction 
after just 4 days of treatment. Interestingly, while saracatinib monotherapy 
showed a treatment-induced reduction in VEGF and MMP2 gene expression, 
when comparing gene expression in combination treated tumours to cedarinib 
monotherapy-treated tumours, expression of these two pro-angiogenic genes 
was significantly increased in the combination arm [Figure 4.6 (b)]. 
 
As Figure 4.8 shows, extended treatment with saracatinib lead to a significant 
reduction in 786-O xenograft growth when compared to control treated 
tumours. IHC analysis did not reveal the mechanism of action. We could find no 
evidence for increased apoptosis or reduced proliferation in the saracatinib arm 
[Figure 4.7].  
 
The primary focus of this work was to investigate the potential of SRC inhibition 
in combination with anti-VEGF treatment. As Figure 4.7 shows, when combined 
with cediranib, saracatinib did provide an additive benefit. Again, IHC analysis 
did not provide a definitive mechanism of action for this effect. Ki67 was not 
significantly different between combination treatment and the cedarinib 
monotherapy arms. Cedarinib significantly increased apoptosis compared to 
vehicle treated tumours and combination therapy further increased the number 
apoptotic cells, but the effect did not reach statistical significance. Conceivably, 
the ability of cediranib to induce apoptosis may be enhanced by saracatinib’s 
ability to reduce STAT3 activity. In addition to regulating VEGF expression, up-
regulation of the STAT3 pathway has been shown to promote anti-apoptotic 
gene expression 112 113. Similarly inhibition of STAT3 has been shown to sensitize 
cells to pro-apoptotic signals, reducing drug resistance 114 115. Further 
investigation of this potential synergistic mechanism of action is warranted. 
 
In the final study 786-O xenografts were pre-treated with sunitinib until all 
tumours displayed a ‘resistant’ phenotype i.e. tumours were growing in response 
to continuous sunitinib treatment having initially regressed in response to 
treatment. Tumours were randomized to either cediranib monotherapy or 
combination therapy. Tumours receiving combination therapy grew less rapidly 
than cediranib monotherapy tumours. However, even tumours receiving 
combination therapy could not be prevented from growing suggesting the 
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molecular mechanisms driving tumour resistance to anti-VEGF therapy could not 
be completely overcome by the addition of the SRC inhibitor [Figure 4.8]. 
Chapter 5 investigates the potential mechanisms of acquired resistance in the 
786-O xenograft. Several pro-angiogenic genes were upregulated in response to 
sunitinib treatment including FGF-2, MET receptor and PGF. A retrospective 
analysis found that the addition of saracatinib to cediranib did not affect gene 
expression of any of these alternative pro-angiogenic factors.   
 
There are a number of shortcomings with the work contained in this chapter. 
Firstly, xenograft work was based on one tumour model with tissue taken at one 
timepoint. Although the addition of the SRC inhibitor seemed to improve efficacy 
compared to anti-VEGF monotherapy, biomarker analysis provided little insight 
into the mechanism of action. Nevertheless, we did show that VHL mutation can 
promote resistance to the direct effect of SRC inhibitors on RCC cell viability. 
Furthermore, we showed saracatinib was capable of inhibiting STAT3 activation 
in an animal model, highlighting one potential mechanism by which SRC 
inhibitors may synergize with anti-angiogenic therapy. Further work is 
warranted to explore these preliminary observations. In particular, biomarker 
analysis using patient tissue from an ongoing study investigating cediranib plus 
saracatinib in sunitinib-resistant patients may provide insight into whether VHL 
status or baseline levels of STAT3 activation have any impact on treatment 
response.  
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Chapter 5: 
Using the 786-O xenograft model to investigate 
VEGF-TKI resistance in Renal Cell Carcinoma  
 
 
5.1 Introduction and aims of chapter 
  
Xenografts have frequently been used to investigate mechanisms of 
angiogenesis and the interaction of tumour cells with their microenvironment. 
Unfortunately the majority of these xenograft models don’t accurately reflect the 
clinical reality of renal cancer. The majority of RCC patients initially benefit from 
anti-angiogenic therapy, but inevitably these tumours develop a resistant 
phenotype over the course of treatment. A model that more accurately reflects 
this pattern of acquired resistance could provide a useful research tool. 
 
Huang et al used 3 different RCC xenograft models that displayed some 
capability of tumour regrowth, after initially responding to sunitinib treatment 39. 
In A498 and SN12C xenograft models a minority of tumours developed a 
resistant phenotype. In contrast, the majority of 786-O tumours (15 out of 18) 
were capable model capable developing a resistant phenotype when exposed to 
continuous sunitinib treatment. By examining plasma taken at study end, the 
authors went on to show that IL-8 was higher in 786-O xenografts 
demonstrating a resistant phenotype (n=15) than xenografts that continued to 
show sensitivity (n=3). Further experiments showed that blocking IL-8 had 
some therapeutic benefit to these 15 resistant tumours. 
 
In line with Huang et al we demonstrated that 786-O xenografts are capable of 
developing a resistant phenotype under continuous therapy, whereas no A498 
xenografts showed any evidence of tumour regrowth when the study was 
terminated (Figure 3.7). The majority of work contained in this chapter aims to 
better characterise the drivers of resistance in the 786-O xenograft model.  
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Tissue was taken at three timepoints; Day 4, Day 22 and Day 57. At Day 4 
tumours had not yet developed resistance to sunitinib treatment. Tissue taken 
at this timepoint was used to perform pharmacodynamic studies to better 
understand sunitinib’s mechanisms of action. Experimental techniques included 
IHC staining of tumour tissue, flow cytometry to investigate the effect on the 
myeloid cells and PCR to investigate gene expression on the tumour and host 
compartments. 
 
By Day 57 tumour growth had rebounded in all cases. By comparing biomarkers 
at Day 4 with tissue taken at later timepoints, we show that dynamic changes 
occurred in gene expression in both the tumour compartment and the host. 
Vessel density showed a modest rebound in resistant tumours and collagen 
deposition increased in treated tumours by the later timepoints. 
 
Finally, tumour tissue taken from RCC patients was used to examine whether 
the xenograft observations are representative of processes occurring in the 
clinical setting.  
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5.2 Results 
 
5.2.1  Pharmacodynamic study investigating sunitinib in the 786-O  
xenograft model 
 
Prior to any work investigating resistance mechanisms, a pharmaco-dynamic 
study was performed using tissue taken after 4 days treatment with sunitinib or 
vehicle. Tissue taken at 4 days was not necrotic allowing entire sections to be 
examined by IHC.  
 
IHC was performed to examine CD31 a tumour vessel marker. CD31 protein was 
specific for tumour vessels [Figure 5.1 (b)] enabling computer-aided 
quantification of vessel density, using visually-trained parameters. Vessel 
density was defined as the percent of total tissue stained positive for CD31 
protein. By Day 4 vessel density was 90% lower in sunitinib treated tumours 
when compared to time-matched vehicle treated controls [Figure 5.1 (b)].   
Mean vessel density was 2.85% in vehicle-treated tumours vs 0.28% in the 
sunitinib arm (p<0.01). 
 
Sunitinib increased cleaved caspase 3 significantly [Figure 5.1 (c)] indicating an 
increase in the number of cells undergoing apoptosis. The proliferation index, 
defined as the proportion of cells staining positive for Ki67, also increased 
significantly in sunitinib-treated tumours.  
 
While vessel reduction and the increase in apoptotic cells could help explain the 
observed effect of sunitinib on tumour size, an increase in the proliferation index 
was not expected. Furthermore, this result was observed in tissue taken after 4 
days of treatment, prior to development of a resistance phenotype. This result 
was further investigated and details can be found in section 5.2.3. 
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Figure 5.1:  Pharmacodynamic study in tissue taken after 4 days treatment 
with sunitinib or vehicle. Panels (a) and (b) show an example of CD31 and its 
quantification (all quantification was done using the ARIOL system with visually trained 
parameters). The example indicates the level of vessel density in a (i) vehicle-treated 
tumour and (ii) sunitinib treated tumour. Panel (d) shows and example of cleaved 
caspase 3 (CC3) IHC in a sunitinib treated tumour. CC3 is a marker of apoptosis. Panels 
(e) and (f) show the effect on proliferation as determined by Ki67 staining. 
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5.2.2 The effect of the VEGF-TKIs sunitinib and cediranib on the myeloid 
compartment 
 
As part of previous work conducted by our group it was observed that spleen 
weights were affected by sunitinib treatment. In this previous study, spleens 
were collected at the end of extended anti-tumour studies 48. The pharmaco-
dynamic study allowed us to investigate whether spleen weights were affected 
over a shorter period. It also allowed us to investigate the effect on different 
myeloid cell types.  
 
Figure 5.2 (c) shows that spleen weights were significantly reduced after 4 days 
of sunitinib treatment. To investigate the effect on the myeloid compartment, 
bone marrows were flushed at necropsy and harvested cells were assessed by 
flow cytometry. By gating cells based on forward and side-scatter, the 
proportion of monocytes, granulocytes and lymphocytes were quantified.  
 
Panels (a) and (b) shows raw flow cytometer data and the gates used to 
distinguish cell types. Gates R1, R2, R3 and R4 were taken to represent red 
blood cells, lymphocytes, monocytes and granulocytes respectively.  
 
Figure 5.2 (d)-(f) shows sunitinib significantly reduced the proportion of 
monocytes and lymphocytes in the bone marrow (both p<0.01), but did not 
have a statistically significant effect on the granulocyte population. The 
experiment was repeated at a further timepoint (Day 22) and with a different 
anti-VEGFr TKI (cediranib) with similar results (data not shown). 
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Figure 5.2:  Pharmacodynamic study using bone marrow harvested after 4 days 
therapy. Panels (a) and (b) show raw flow cytometer data - gates R1, R2, R3 and R4 
were taken to represent red blood cells, lymphocytes, monocytes and granulocytes 
respectively. Panels (d) - (f) shows the results of the analysis on the different cell types. 
Panel (c) shows the difference in spleen weights harvested from mice after 4 days 
therapy.  
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5.2.3 The impact of sunitinib on tumour-associated myeloid cells  
Flow cytometry established an effect on myeloid cells in the bone marrow and 
spleen weights suggested an effect on circulating myeloid cells. Furthermore, 
data using human and mouse-specific PCR indicated a significant reduction in 
host cells within the tumour [Figure 5.3 (a)]. IHC was used to investigate 
whether this translated to a reduction in myeloid-derived cells within the tumour 
microenvironment. IHC staining for F4/80 positive cells was used to quantify 
macrophage content. Panels (b) and (d) indicate that macrophages were 
abundant in 786-O tumours and represented a significant proportion of non-
tumour cells at the tumour site (unlike epithelial derived tumour cells epithelial 
derived murine cells do not stain positive for cytokeratin). Quantification of the 
F4/80 staining of vehicle of sunitinib-treated tumours indicated sunitinib 
significantly reduced macrophage content by 4 days. 
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Figure 5.3: The effect of sunitinib on stromal cells in situ. Panel (a) shows the 
result of a PCR experiment to quantify the relative amount of tumour and host cells at 
the tumour site. Human and mouse-specific probes for 18s demonstrated fewer mouse 
cells were present in tissue taken from sunitinib-treated tumours. Panel (b) is an 
example of pan-cytokeratin staining which indicates which cells are of human origin and 
so tumour cells. Panel (d) shows and example of F4/80 staining for macrophages and 
panel (c) shows the effect of sunitinib on the macrophage content of 786-O xenografts. 
(a) Sunitinib effect on murine 18s
(c) Sunitinib effect on F480
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Xenograft sections were stained for Ki67 to investigate treatment effect on cell 
proliferation. Ki67 staining was not homogenous.  In fact the pattern of positive 
cells was similar to that seen in cytokeratin staining [Figure 5.4 (a) and (c)]. 
Since sunitinib had reduced both macrophages and vessels at the tumour site, 
we hypothesised that a sunitinib-induced reduction in non-malignant cells could 
explain the earlier observation that sunitinib increased the proportion of 
Ki67+ve cells [Figure 5.1 (e)].  
In order to test this hypothesis, sections were dual-stained for Ki67 and 
cytokeratin by IFC and the results visualised by confocal microscope [Figure 5.4 
(d)]. Counting cells positive for both cytokeratin and Ki67 allowed us to quantify 
the proportion of proliferating cells in the tumour compartment. Sunitinib 
treatment had no effect on the proportion on tumour cells that were Ki67+ve 
(data not shown) supporting our hypothesis. 
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Figure 5.4: The effect of sunitinib on Ki67 staining in the tumour compartment 
of 786-O xenografts. Panels (a) – (c) shows examples of IHC stains; (a) pan-
cytokeratin distinguishes tumour cells, (b) F480 stains for macrophages (c) shows the 
pattern of Ki67 staining. Panel (d) shows the result of tumour dual stained for 
cytokeratin (green) and Ki67 (red). DAPI (blue) shows cell nuclei. 
100 microns
(a) Example of cytokeratin staining
(c) Example of Ki67 staining
(b) Example of F480 staining
(d) Dual staining for cytokeratin/Ki67 
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5.2.4 The effect of sunitinib treatment on gene expression in tumour 
cells and the host compartment 
 
In the clinical setting, sunitinib can generate tumour responses and 
improvements in Progression Free Survival (PFS), but acquired resistance 
translates to a limited long term survival benefit. Pre-clinical studies aimed at 
explaining drivers of acquired resistance have focused on several mechanisms 
including: 
 
- Angiogenic factors such as basic fibroblast growth factor (FGF-2), the 
hepatocyte growth factor (HGF) / MET receptor pathway and placental 
growth factor (PGF) that can complement VEGF-A, providing alternative 
mechanisms to recruit endothelial cells and promote their growth in situ.  
- Inflammatory cytokines and host immune / myeloid cells, which can also 
drive angiogenesis and support tumour progression.  
- An increase in metastatic potential, driven by the tumour cell ability to 
invade local tissue before travelling to distant sites. Genes involved in 
matrix remodeling, such as the matrix metalloproteases and genes 
involved in a tumour cell’s motility and adhesion such as snail, slug and 
the cadherins may help drive this process. 
 
To investigate what was driving resistance in the 786-O model a panel of genes 
thought to be involved in angiogenesis, metastasis and tumour-stromal 
interaction were selected. PCR probes for these genes were tested for specificity 
for human or mouse (this work was carried out at AstraZeneca independently of 
this project). In this way, gene expression in the tumour and host 
compartments of 786-O xenografts could be investigated separately. 
 
Tissue was taken at 3 timepoints (unlike the Huang et al which only reported on 
tissue taken at study completion). This allowed investigation of dynamic 
changes to relevant biomarkers over the course of treatment and disease 
progression; tissue from sensitive tumours was taken after 4 days of therapy, 
tissue was taken again after sustained treatment (22 days) and finally at 57 
days when all tumours were displaying a resistant phenotype (Figure 5.5).  
VEGF-TKI resistance in Renal Cell Carcinoma 
 
 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5:  Experiment design allowed tissue to be taken at three timepoints. 
At Day 4 tissue from vehicle and sunitinib-treated was taken. Sunitinib-treated tumours 
were sensitive to sunitinib at this time-point (n=7 in the vehicle arm and n=5 in the 
treatment arm). Tissue was taken from both arms at Day 22 (n=7 in the vehicle arm 
and n=5 in the treatment arm). This was the latest time-point available to take tissue 
from vehicle-treated tumours because tumour size was approaching the limit allowable 
under the project license. Finally tissue was taken at Day 57 (n=15). By this timepoint 
all tumours were growing (>20% growth from the lowest measurement taken in all 
cases) and so were classified as displaying a resistant phenotype. 
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High throughput PCR (Fluidigm) was performed on tissue taken at the 3 
different time-points using species-specific assays (n=7 for vehicle, n=5 for 
sunitinib-treated tumours). The proportion of human and mouse tissue in each 
sample was controlled for with primers targeting human and mouse specific 18s 
rRNA primers.  
After removing results from genes that did not produce Ct values within 40 
cycles, we generated data for 112 human-specific and 156 mouse-specific 
primers. Figures 5.6 and 5.7 show gene expression data generated from human 
and mouse-specific probes respectively. Delta-delta-CT values were calculated 
with reference to the mean CT value of vehicle treated in tissue taken at 4 days. 
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Figure 5.6: Gene expression data relating to the tumour compartment of 786-O 
xenografts. At Day 4 sunitinib-treated tumours were classed as sensitive to treatment, whereas 
all tumours displayed a resistant phenotype by day 57. Species-specific probes were used, with 
the data above relating to probes validated as specific to cells of human origin, but not murine 
cells (the host compartment). 
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Figure 5.7: Gene expression data relating to the host compartment of 786-O xenografts. 
At Day 4 sunitinib-treated tumours were classed as sensitive to treatment, whereas all tumours 
displayed a resistant phenotype by day 57. Species-specific probes were used, with the data 
above relating to probes validated as specific to cells of murine origin, but not human cells (the 
tumour compartment). 
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Two genes with significantly different expression profiles between sunitinib-
treated and vehicle-tumours were chosen to validate the gene expression data 
at the protein level. In terms of the tumour compartment (Figure 5.6), the three 
genes with the largest fold-increase in gene expression at Day 57 versus Day 4 
(vehicle) were PGF (placental growth factor, 12.2-fold increase, p<0.01) ENG 
(endoglin, 8.9-fold increase, p<0.01) and S100A4 (6.4-fold increase, p<0.01). 
These genes were selected to validate the gene expression data.  
 
To investigate the increase in PGF, an ELISA was performed on serum harvested 
from both vehicle and sunitinib-treated mice at the 3 time-points. As Figure 5.8 
(d) - (e) shows, PGF concentration was significantly increased at Day 57. When 
data was normalised to allow for differences in tumour size, PGF concentration 
was 11.6-fold higher in sunitinib-treated mice (Day 57) than (Day 4) vehicle-
treated mice (p<0.01). This was consistent with the earlier gene expression 
analysis. 
 
To quantify S100A4 and endoglin protein expression levels, IHC was performed 
on whole xenograft sections. Although endoglin could be visualised in the 
vessels of human tumours (used as a positive control) the protein could not be 
visualised in any xenograft sections including sunitinib-treated tumours 
harvested at Day 57 (concentrations up to 1:3 were tried).  S100A4 protein 
could be visualized by IHC. Examples of staining can be seen in Figure 5.8 (a) – 
(b). Quantification using image analysis software with visually trained 
parameters confirmed S100A4 protein was significantly increased in ‘resistant’ 
Day 57 tumours as compared to tissue taken at Day 4 (p<0.01). This was 
consistent with the earlier gene expression analysis. 
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Figure 5.8: Validation of gene expression data at the protein level. Panel (a) and (b) show 
examples of S100A4 staining from tissue taken at Day 4 and Day 57 respectively. Panel (c) shows 
the quantification of staining results using image analysis software with visually trained 
parameters. Panels (d) and (e) show the results of an ELISA performed to quantify PGF levels in 
the serum of mice harvested at days 4, 22 and 57. Panel (e) normalised the data to take into 
account the difference in tumour size between the various study groups. 
 
 
 
 
 
(a) Example of S100A4 staining in 
tissue taken at 4 days 
  
(b) Example of S100A4 staining in 
resistant model 
(c) Quantification of S100A4 IHC 
staining 
(d) PGF quantification by ELISA (raw data) (e) PGF quantification by ELISA (normalised to take 
into account tumour size) 
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Results of the gene expression analysis showed that multiple pro-angiogenic 
ligands were up-regulated in sunitinib-treated tumours in both the host and 
tumour compartments. In the host compartment VEGF-A, PGF, FGF-2, HGF and 
its target MET receptor were all significantly up-regulated by Day 22 [Figure 5.9 
(d)]. Furthermore, the anti-angiogenic ligand DLL4 was significantly down-
regulated.  
 
In the tumour compartment, VEGF-A and PGF were up-regulated by Day 22 
[Figure 5.9 (c)], but FGF-2, HGF and DLL4 were not significantly different (data 
not shown). Both VEGF-A and PGF are known to be regulated by the HIF-1 and 
HIF-2 transcription factors. A separate PCR confirmed up-regulation of the HIF-2 
transcription factors (the 786-O cell line is HIF-1 null).  
 
CD31 staining showed that vessel density continued to reduce after Day 4 
reaching a minimum vessel density at Day 22. After this, a modest but 
significant rebound occurred by Day 57 (the ‘resistant’ tumours). In these 
tumours, vessels were not homogenously distributed but were present in 
patches, which were also populated by a high proportion of non-endothelial host 
cells. An example of this can be seen in Figure 5.9 (b). 
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Figure 5.9: Up-regulation of multiple pro-angiogenic factors and rebound in vessel 
density. Panel (a) shows that vessel density rebounds with time as tumours become resistant to 
sunitinib. An example of CD31 staining in ‘resistant’ tumours is shown in panel (b). Panel (c) 
shows the tumour compartment up-regulates VEGF-A and PGF ligands. While panel (d) shows 
non-malignant host cells upregulate VEGF-A to a much more significant degree as well as a 
number of other alternative angiogenic factors including FGF-2 and the HGF-Met receptor 
pathway.   
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In addition to genes associated with angiogenesis, Figure 5.6 shows that 
treatment affected a number of other genes implicated in tumour progression. 
When comparing sunitinib-treated tumours to their corresponding vehicle-
treated controls, a number of genes were significantly up-regulated in treated 
tumours including several inflammatory factors (including IL-6, CCL5, CXCL10), 
proteases involved in tissue remodeling (MMP2, cathepsin b) and genes central 
to the clotting system (tissue plasminogen activator, SERPINE1 and SERPINE2). 
In the majority of cases, these genes are most affected at Day 22 when 
treatment had its maximum effect on vessel density reduction [the four most 
up-regulated genes at Day 22 can be seen in Figure 5.10 (a)]. 
A comparison was made between vehicle groups at Day 4 and Day 22 to 
investigate whether genes were changing with time independently of treatment. 
In the tumour compartment 10 genes (cathepsin b, CCL2, cytokine-like 
protein1, FGF18, IL1 receptor1, IL6 receptor, neuroplin1 , neuropilin 2, placental 
growth factor, S100A4) were significantly up-regulated in vehicle treated 
tumours at Day 22 versus Day 4 (all p<0.05). A further two genes (MMP9 and 
MMP13) were significantly down-regulated at Day 22 versus Day 4 (p<0.05).  
Of the 10 genes up-regulated at the later timepoint, three genes (placental 
growth factor, FGF18 and S100A4) were up-regulated in sunitinib-treated 
tumours at Day 57 compared to both the vehicle and sunitinib arms at Days 4 
and 22 [see Figure 5.10 (b)]. Consistent with this data at the gene expression 
level, placental growth factor concentration levels were significantly up-
regulated in the serum of mice at Day 22 versus Day 4 in vehicle-treated 
tumours. Concentration levels continued to increase and by Day 57 PGF was 
significantly higher than either sunitinib or vehicle-treated tumours at Day 22 
[see Figure 5.8 (e)]. 
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Figure 5.10: Gene up-regulation in the tumour compartment. Panel (a) show examples of 
inflammatory, protease and clotting genes significantly up-regulated in sunitinib-treated tumours 
at Day 22. Panel (b) shows and example of two genes up-regulated in vehicle-treated tumours at 
Day 22 versus Day 4, which are also significantly up-regulated in sunitinib-treated tumours at Day 
57 compared to Day 22.   
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(a) Genes up-regulated in the tumour compartment by sunitinib  
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(b) Genes up-regulated in ‘sunitinib-resistant’ tumours that are also up-regulated in 
vehicle-treated tumours at Day 22 versus Day 4 
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One of the proposed mechanisms of resistance is a treatment, or hypoxia, 
induced increase in the tumours metastatic potential. Genes thought to be 
involved in this process include proteases involved in invasion and tissue 
remodeling (which could derive from both the tumour and host compartments) 
in addition to genes involved in tumour cell’s epithelial to mesenchymal 
transition.  
 
A number of proteases were up-regulated in both the tumour and host by Day 
22 compared to the corresponding vehicle-treated tumours. These included 
MMP2 [3.4-fold increase in the tumour (p<0.01) and 3.6-fold increase in the 
host (p<0.01)] and MMP9 [no significant up-regulation in the tumour, but a 2.3-
fold increase in the host (p<0.01)].  
 
In terms of genes indicating an epithelial-to-mesenchymal transition in the 
tumour compartment, the transcription factor SNAIL was significantly up-
regulated at Day 22 [2.2-fold increase (p=0.04)]. However, although there was 
a decrease in E-cadherin (CDH1) and an increase in CDH11, a cadherin whose 
expression is associated with a mesenchymal phenotype, neither of these 
changes quite reached statistical significance [CDH1 2.8-fold decrease (p=0.06) 
and CDH11 1.9-fold increase (p=0.06)]. 
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Figure 5.11: Gene expression of genes in the tumour compartment thought to regulate 
epithelial-to-mesenchymal transition. 
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5.2.5 The potential role of methylation in the ‘sunitinib-resistant’ 
phenotype  
 
S100A4 was significantly up-regulated in ‘resistant’ tumour tissue taken at Day 
57 when compared to treated tissue at Day 4, However, at Day 22 protein levels 
were not significantly different between sunitinib-treated and vehicle-treated 
tumours. S100A4 has been shown to be associated with metastasis. An inverse 
relationship between e-cadherin has been noted and recently one group has 
shown that overexpression of S100A4 can drive metastasis in a RCC xenograft 
model 116. This same group noted that S100A4 was regulated by methylation. 
 
Using O-miner, an online tool developed at Barts Cancer Institute that allows re-
analysis of gene expression data taken from publicly deposited raw microarray 
data files, a panel of RCC cell lines was re-analysed to investigate which genes 
were most up-regulated when treated with the de-methylation agent 5-
azacytidine. In line with previous findings S100A4 was among the most affected 
genes. Interestingly, placental growth factor, which was also highly up-regulated 
at Day 57, also appeared among the list of most up-regulated genes.  
 
786-O cells were de-methylated with 5-azacytidine in vitro and PCR was 
conducted to investigate S100A4 and PGF expression. De-methylation was found 
to significantly up-regulate both S100A4 [log-fold change 4.3 (p<0.01)] and 
PGF [log-fold change 5.0 (p<0.01)] confirming previous microarray data. 
 
To date, ‘resistant' xenograft tumours have not been investigated for changes in 
methylation status. 
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Gene symbol  Gene name  Log‐fold change  Gene location
DAZL  deleted in azoospermia‐like  6.041207250  3p24.3
CCL20  chemokine (C‐C motif) ligand 20  5.491894177  2q33‐q37
GTSF1  gametocyte specific factor 1  5.257688717  12q13.13
MAEL  maelstrom homolog (Drosophila)  5.118489475  1q24.1
MMP1  matrix metallopeptidase 1   4.607410577  11q22.3
NFE4  transcription factor NF‐E4  4.595544903  7q22.1
COL1A1  collagen, type I, alpha 1  4.175204324  17q21.33
WDR66  WD repeat domain 66  4.159705878  12q24.31
COL1A1  collagen, type I, alpha 1  4.109540555  17q21.33
GREM1  gremlin 1  4.057677289  15q13.3
COL6A3  collagen, type VI, alpha 3  4.020847357  2q37
GREM1  gremlin 1  3.973137918  15q13.3
HORMAD1  HORMA domain containing 1  3.573127135  1q21.3
LAPTM5  lysosomal protein transmembrane 5  3.471547104  1p34
CST6  cystatin E/M  3.463559096  11q13
LOC654433  hypothetical LOC654433  3.404553620  2q13
LY6K  lymphocyte antigen 6 complex, locus K  3.336944199  8q24.3
H19  H19  3.329118595  11p15.5
S100A4  S100 calcium binding protein A4  3.199693292  1q21
SFN  Stratifin  3.080317536  1p36.11
HCLS1  hematopoietic cell‐specific Lyn substrate 1  3.001811876  3q13
SYCP3  synaptonemal complex protein 3  2.947403641  12q
DENND2A  DENN/MADD domain containing 2A  2.883159126  7q34
PSG9  pregnancy specific beta‐1‐glycoprotein 9  2.705099983  19q13.2
FERMT3  fermitin family member 3  2.660193311  11q13.1
ISG20  interferon stimulated exonuclease gene 20  2.652711541  15q26
KRT34  keratin 34  2.583364730  17q21.2
PGF  placental growth factor  2.568622368  14q24.3
LOC728449  hypothetical protein LOC728449  2.557249674  10q11.22
CCL5  chemokine (C‐C motif) ligand 5  2.495092384  17q11.2‐q12
 
Table 5.1: Genes most significantly up-regulated when a panel of RCC cell lines were 
treated with the de-methylation agent 5-azacytidine.  
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5.2.6 Sunitinib up-regulates genes associated with fibrosis and is 
associated with increased collagen deposition 
 
Using the gene expression data, Ingenuity Pathway Analysis (IPA) was 
conducted to better understand processes and pathways involved with 786-O 
resistance. This was conducted separately in the tumour compartment and the 
host compartment respectively. 
 
Table 5.1 shows the results of the IPA analysis suggesting genes up-regulated in 
the 786-O. Interestingly, genes associated with fibrosis were consistently up-
regulated in both tumour and host gene expression pathway analysis. Fibrosis is 
characterised by excessive deposition of connective tissue components, 
particularly collagen. In order to investigate whether up-regulation of fibrosis-
related genes was accompanied by increased collagen deposition, tumours were 
stained with sirius red. Collagen content was quantified using image analysis 
software. As Figure 5.12 shows, collagen density at the tumour site was 
significantly increased by sunitinib treatment.  
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  Tumour compartment 
  Day 22 - sunitinib v’s vehicle sunitinib resistant (Day 57) v’s sunitinib sensitive (Day 4) 
1 Coagulation  Hepatic Fibrosis 
2 Hepatic Fibrosis Coagulation  
3 Glioma invasiveness Macrophages, Fibroblasts & Endothelial in RA 
4 Macrophages, Fibroblasts & Endothelial in RA Glioma invasiveness 
5 Osteoclasts and osteoblasts in RA Ephrin receptor signalling 
 
   
  Host compartment 
  Day 22 - sunitinib v’s vehicle sunitinib resistant (Day 57) v’s sunitinib sensitive (Day 4) 
1 Hepatic Fibrosis Hepatic Fibrosis 
2 Bladder Cancer IL-8 signaling 
3 IL-8 signaling Glioma invasiveness 
4 Clathrin-mediated endocytosis Stem cell pluripotency 
5 FGF signaling Axonal guidance signalling 
 
 
Table 5.2: Results of Ingenuity pathway analysis: All genes whose expression was 
significantly affected (p<0.05) by sunitinib-treatment (column 1) or the resistance process 
(column 2) were included in the IPA analysis. 
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Figure 5.12: Results of staining for collagen density in vehicle and sunitinib treated 
tumours. Panel (a) shows an example of a sunitinib-treated tumour stained for collagen. Panel 
(b) indicates that collagen was significantly denser in sunitinib-treated tumours than the 
corresponding vehicle-treated tumours.  
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5.2.7 Investigating whether key xenograft findings occur in the clinical 
setting 
 
VEGFr-TKI treated RCC patient tissue was used to investigate whether 
unexpected findings from the xenograft model were occurring in the clinical 
setting.  
 
Cells of myeloid origin were significantly decreased in sunitinib-treated tumours 
both in the bone marrow and at the tumour site. Tumours were stained for total 
myeloid cell content by targeting CD45. As 5.13 (a) shows there was no 
significant difference in total myeloid content between the two groups.  
 
In flow cytometry analysis of xenograft’s bone marrow, the proportion of 
lymphocytes was significantly reduced. RCC samples were stained for CD3 +ve 
cells, a marker of T lymphocytes. No difference was seen between the pre- and 
post-treatment samples [Figure 5.13 (b)]. However, the proportion of FOXP3 
+ve cells was significantly reduced [Figure 5.13 (c)]. FOXP3 is thought to be a 
marker of T-reg cells a subset of T-lymphocytes. 
 
The RCC patient tissue was a combination of sunitinib (n=58) and pazopanib-
treated (27) samples. For all biomarkers stained, including all markers in 
Chapter 3 (CD31, FGF-2, Met receptor, Ki67) and markers in data not presented 
in this thesis (phosphorylated s6K and PDL-1) a comparison was made between 
the effects of the two drugs. In the majority of cases, there was no difference in 
the effects of the 2 drugs. However, sunitinib but not pazopanib, resulted in a 
significant reduction in the expression of CD45 and CD3 [median change -84% 
vs. +13% (p<0·05); median change -38% vs. +117% (p<0·05) respectively]. 
 
TMAs were constructed avoiding necrotic regions and areas with a high 
proportion of connective tissue. Consequently we used whole sections to the 
effects of sunitinib treatment on collagen deposition.  
 
 
 
 
 
As seen in the xenograft tumours, sunitinib treatment (12-16 weeks of therapy) 
was associated with a significant increase in collagen density at the tumour site 
(Figure 5.14). 
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Figure 5.13: VEGFr-TKI treated RCC patient tissue stained for the immune markers CD45 
(all myeloid cells) CD3 (T cells) and FOXP3 (T-reg cells). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Comparison of collagen density staining of VEGFr-TKI treated and 
untreated RCC patient samples. Panel (a) shows an example of a low collagen density 
untreated tissue sample and a treated tissue sample with high collagen density as seen by the 
increased amount of Sirius Red.  Panel (b) indicates that collagen was significantly denser in 
sunitinib-treated tumours.  
 
(a) Examples of collagen staining (b) Quantification of collagen 
(a) CD45 quantification (b) CD3 quantification (c)  FOXP3 quantification 
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5.3 Discussion 
 
Before looking for resistance mechanisms, xenograft tissue taken after 4 days of 
treatment was used to examine the pharmacodynamics effect of sunitinib 
treatment on 786-O tumours. The 4-day time point was chosen because it was 
thought to provide enough time for pharmacodynamics effects to take place, but 
not too long for treated tumour sizes to be significantly different from vehicle 
treated controls. Nevertheless, the fact that we only have tissue from this one 
timepoint is a limitation of this study. Furthermore, the choice to take tissue 2 
hours after the last sunitinib (or vehicle) dose provides another important 
limitation, particularly in the context of trying to measure biomarkers that are 
thought to change significantly over treatment cycles, such as the anti-apoptotic 
marker, cleaved caspase 3.  Notwithstanding these limitations, IHC analysis 
conducted on this tissue did provide some interesting insights.  
 
Sunitinib is thought to work primarily by reducing tumour vessel density thereby 
decreasing oxygen and nutrient supply to malignant cells. 4 days after 
treatment onset tumour vessel density was already 90% lower in sunitinib-
treated xenografts than in vehicle controls [Figure 5.1 (a)]. Given that these 
tumours had grown for 28 days prior to treatment onset, this degree of 
reduction suggests sunitinib pruned existing vessels in this xenograft, rather 
than simply reducing new vessel formation.  
 
A 90% decrease in tumour vessel density after just 4 days suggests the 
sunitinib dose used in the 786-O model had a much more significant effect than 
we may expect to take place in the clinical setting. A pre- and post-treatment 
analysis in the clinical setting saw a 49% median decrease in tumour vessel 
density [Section 3.1]. This highlights a further limitation of our xenograft work. 
Many of the dynamic changes seen in biomarkers, such as changes in gene 
expression, may be indirect results of the hypoxic environment caused by 
sunitinib in this model. If this model is not representative of the clinical setting, 
it reduces our ability to translate these findings into a meaningful context. 
 
FACS analysis on the bone marrow at Day 4 revealed a significant immune-
suppressive effect. Furthermore, PCR results using human and mouse-specific 
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18s probes indicated a significant reduction in non-malignant cells at the tumour 
site. Due to size of this effect, and previous IHC staining that revealed that 
vessels comprised approximately 3% of the total tissue, we hypothesized that 
sunitinib was impacting other non-malignant cells, in addition to endothelial 
cells. IHC staining showed that sunitinib reduced macrophage content at the 
tumour site.  
 
To investigate whether a similar effect was occurring in the clinical setting, RCC 
tumour samples pre- and post- anti-VEGFr treatment were stained for CD45, a 
common marker for cells of haematopoietic origin. No difference in the percent 
of CD45+ve cells was seen between pre- and post-treatment tissue. A subgroup 
analysis looking at patients treated with sunitinib (excluding patients treated 
with pazopanib) a significant reduction in CD45 cells was seen post-treatment. 
Previous work taking peripheral blood from patients before and after sunitinib 
treatment suggests sunitinib is having a myelosuppressive effect, at least in 
peripheral blood 45. To our knowledge no previous work has shown a reduction 
in myeloid cells at the tumour site of RCC patients following anti-VEGFr 
treatment. In addition to their role in immune evasion 44, myeloid cells are 
thought to supply pro-angiogenic ligands and so promote resistance to anti-
VEGFr therapy resistance 45 117. Conceivably a reduction of certain myeloid cells 
at the tumour site could contribute to sunitinib’s observed efficacy. However, 
our subgroup analysis looking at sunitinib-treated patients only, reduces an 
already modest sample size and limits our ability to draw conclusions with any 
confidence. 
 
A similar subgroup analysis, looking at patients who received sunitinib 
specifically, showed that treatment significantly reduced CD3 cells at the tumour 
site. Preclinical models have previously suggested that directly targeting VEGFR-
2 does not impede T-cell infiltration at the tumour site, but may in fact promote 
infiltration through vascular normalization 118. However, sunitinib is multi-
targeted TKI, which affects several other kinases at clinically relevant doses. 
Other groups have shown that sunitinib can reduce T-cell proliferation 119. 
Sunitinib and pazopinib impact other kinases to different degrees. It is possible 
that sunitinib has a direct off-target effect on immune cells which does not 
happen with pazopinib therapy and the pre and post-treatment tissue IHC 
corroborates our xenograft work suggesting that sunitinib significantly decreases 
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immune infiltrate at the tumour site. Different agents have previously been 
reported to have effects on different subsets of immune cells 120. Again, our 
subgroup analysis is based on a small sample size reducing our ability to draw 
conclusions with confidence. 
 
FOXP3, a marker for regulatory T cells, is the one immune biomarker that did 
reduce significantly when analyzing the pre- and post-treatment samples as a 
whole i.e. not relying on a subgroup analysis focusing specifically on sunitinib-
treated patients [Figure 5.6 (c)]. Sunitinib’s ability to reduce FOXP3 T cells has 
previously been reported 45, 64. Again this previous work focuses on peripheral 
blood rather than tumour tissue. It has been suggested that the effect on FOXP3 
cells is mediated directly through the VEGF-A/VEGFR2 rather than any off-target 
kinase inhibition 121. If the VEGF pathway is the main pathway involved it may 
help explain why this effect was seen in both sunitinib and pazopinib patient 
tissue. Regardless of the pathways involved, the ability to reduce FOXP3 cells at 
the tumour site may contribute to improved outcomes associated with anti-
VEGFr therapy. 
 
Turning to the tumour compartment, our pharmacodynamics analysis on the 
786-O xenograft model showed an increase in the apoptotic marker cleaved 
caspase 3 in sunitinib-treated tumours. Sunitinib has been suggested to act 
directly on cells to induce apoptosis in part through reduction in STAT3 activity 
65, 96. We found no evidence that sunitinib had any effect on STAT3 activity in 
this model [Figure 4.5 (c)]. Furthermore, there was no evidence for a change in 
gene expression of pro- and anti-apoptotic genes thought to be regulated by 
STAT3 such as BCL-XL and BCL-2 (data not shown). We cannot rule out a direct 
effect on tumour cells leading to apoptosis, mediated by a different pathway, 
but the increase in apoptosis may be explained by the observed reduction in 
vessel density, reducing oxygen supply and nutrients to tumour cells. We could 
not validate this finding in our RCC patient tissue (data not shown). This could 
have been partly due to the time delay between the last treatment dose and the 
nephrectomies being performed, but we also experienced technical difficulties 
with cleaved caspase staining that may have masked any effect. Tumour tissue 
appeared susceptible to non-specific staining that made quantification of cleaved 
caspase positive tumour cells a difficult task. 
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An increase in the percentage of Ki67 was also observed at Day 4. Because of 
the pattern of staining, and evidence that the proportion the host had decreased 
in sunitinib-treated tumours [Figure 5.3], we hypothesized that this effect was 
driven by a reduction in the proportion on less proliferative non-malignant cells 
in the tissue analyzed, rather than an effect on the tumour cells themselves. 
Subsequent dual-staining for Ki67 and cytokeratin confirmed this [Figure 5.4 
(d)]. Furthermore, we saw no increase in the percentage of Ki67 in the tumour 
compartment at later time periods. As such, we could find no evidence in the 
786-O xenograft to support our observation in clinical tissue that anti-VEGFr 
treatment promotes a more proliferative, aggressive phenotype which may 
contribute to resistance [Figure 3.5]. 
 
The primary reason for conducting the xenograft studies was to look for 
mechanisms of resistance. By replicating the 786-O xenograft model employed 
by Huang et al 39 we were able to obtain xenograft tissue while tumours were 
sensitive to treatment (Day 4) and at a later date when tumours were classified 
as “resistant” since tumour growth had rebounded in all 15 tumours having 
initially shrunk in response to treatment (Day 57). We also obtained tissue at 
Day 22. This timepoint is more difficult to characterize since it could be seen as 
the point of maximum response but could equally be seen as a timepoint when 
many of the resistance mechanisms driving regrowth of tumours were already in 
place [Figure 5.5].  
 
In all 15 tumours that were treated for 57 Days, the initial response to 
treatment lead to a tumour volume decrease that was in excess of 30%, the 
required threshold to be classified as a Partial Response under RECIST criteria 
122. Furthermore, in 15/15 tumours regrowth was in excess of 20%, the 
threshold that must be exceeded to be classified as Progressive Disease under 
RECIST guidelines.  
 
PCR analysis was conducted on the tissue taken at each timepoint to look 
dynamic changes in gene expression that may highlight resistance mechanisms 
in the 786-O model. Rather than looking for specific genes, an effort was made 
look for pathways and processes that were potentially contributing to resistance. 
Moreover, although the use of mouse and human specific probes allowed us to 
investigate the host and tumour compartments separately, an effort was made 
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to look for potential co-operation between the two compartments. Unsurprisingly 
a number of pro-angiogenic genes were upregulated in both the host and 
tumour compartment [Figures 5.6, 5.7 and 5.9]. Up-regulation of these genes 
was most significant at Day 22 which was also the timepoint when vessel 
density was at its lowest [Figure 5.9 (a)]. Presumably host and tumour cells up-
regulated genes in compensation to the hypoxic microenvironment and hypoxia 
was greatest at Day22.  
 
Pro-angiogenic genes were up-regulated to a greater degree in host cells 
compared to the tumour compartment. This is perhaps unsurprising since many 
of these genes such as VEGF-A or MET receptor are known to be mediated by 
the VHL-HIF pathway. Under hypoxic conditions the transcription factor HIF-
alpha is allowed to stabilize resulting in up-regulation of pro-angiogenic genes 8. 
While this process is likely to have driven the observed increase in VEGF-A and 
other pro-angiogenic genes in host cells, the tumour compartment, consisting of 
VHL-null cells would not have experienced the same process. Since 786-O cells 
are VHL-null, the HIF-alpha transcription factors are not labeled for proteasomal 
degradation even under normoxic conditions i.e. HIF-alpha was allowed to 
stabilize even in vehicle treated tumours and so the difference between pro-
angiogenic gene expression in vehicle and sunitinib-treated tumours was not so 
great. The increase in VEGF-A in the tumour compartment could be explained by 
increased HIF-2 gene expression [Figure 5.9 (c), note 786-O cells are HIF-1 
null]. 
 
HIF transcription factors are also thought to regulate certain genes associated 
with metastasis and the promotion of mesenchymal phenotype such as SNAIL 20. 
Interestingly, SNAIL was up-regulated in the tumour compartment versus time-
matched vehicle controls [p<0.05, Figure 5.5]. E-cadherin, which is thought to 
be negatively regulated by SNAIL was decreased at the same time point, but 
this decrease fell short of statistical significance (p=0.06). These results 
highlight one potential resistance mechanism that may be invoked in response 
to anti-angiogenic therapy.  
 
Many other genes were up-regulated at Day 22. Of note several inflammatory 
genes were effected in both the tumour and host compartments including IL-6 
which was significantly up-regulated in both compartments. As noted previously 
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with the up-regulation of several pro-angiogenic genes, the increase in 
inflammatory gene expression was greatest at Day 22. Although Huang et al 
reported that sunitinib decreased IL-8 expression and “reactivation of tumor 
angiogenesis was accompanied by a significant increase of IL-8 release” 39, we 
found neither a decrease in IL-8 in sensitive tumours at Day 4 nor an increase in 
IL-8 in resistant tumours at Day 57. Since we were investigating gene 
expression and Huang et al used ELISA assays, it may be that the decrease and 
subsequent increase occurred at the protein level. However, Huang et al based 
their conclusion taken at one time point (study end) after comparing IL-8 levels 
in tumours that had a resistant phenotype with tumours that failed to rebound 
to draw conclusions. In the Huang et al study, tumours that showed a resistant 
phenotype had similar levels of IL-8 to non-treated controls. It seems 
conceivable that the conclusion of Huang et al was incorrect. Rather than 
decreasing before rebounding to the original levels as they suggest, IL-8 may 
remain at a constant level throughout the treatment course. 
 
The significant modulation of inflammatory markers is interesting in the context 
of the earlier discussion of FOXP3 T cells. The up-regulation of several pro-
inflammatory cytokines provides another potential mechanism by which sunitinib 
may improve type 1 T cell function.  
 
Our PCR analysis revealed several genes that were significantly up-regulated at 
Day 57 despite sunitinib seemingly having little effect on gene expression when 
treated tumours were compared with time-matched controls at Day 22. PGF and 
S1004a both fall into this category. Interestingly, both genes were up-regulated 
in vehicle-treated tumours at Day 22 compared to vehicle-treated tumours at 
Day 4. This raises the possibility that time rather than treatment is the key 
driver of the observed up-regulation of these 2 genes. That is to say that PGF 
and S100A4 were up-regulated as a result of the natural progression of disease. 
Interestingly, although sunitinib may not be directly causing the up-regulation of 
PGF or S100A4, both genes could contribute to sunitinib resistance, PGF by 
promoting new vessel formation and S100A4 through promotion of a 
mesenchymal, metastatic phenotype.  
 
Both PGF and S100A4 are known to regulated in part by methylation. We 
showed that 786-O cells significantly up-regulate both genes in response to a 
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de-methylation agent. Further work could demonstrate whether this was the 
mechanism involved in the 786-O xenograft model. 
 
Ingenuity Pathway analysis was conducted in an effort to better explain what 
pathways were involved in the resistance process. The suggestion that several 
genes involved in fibrosis were up-regulated, lead us to look for collagen 
deposition. Sunitinib was demonstrated to significantly increase collagen content 
in the 786-O xenograft model and we then validated that this process was 
occurring in the clinic using RCC patient tissue. Collagen is thought to promote 
blood vessel development and contribute to pathological angiogenesis 123 124 125. 
Collagen is also thought to promote tumour cell metastasis 126. Consequently, 
increased collagen deposition could promote the resistance process through both 
tumour revascularization and increasing the tumour’s metastatic potential.  
 
One limitation of our work is that although we demonstrate sunitinib increases 
collagen deposition in both xenograft and RCC sample tumours, we did not 
characterise the collagen type. Although 90% of collagen in the human body is 
Type 1 127, which is thought to be pro-angiogenic and metastasis promoting, we 
cannot discount increased deposition of other collagens such as type XVIII 
collagen, which are thought to have anti-angiogenic properties. 
 
There are several other limitations to the work carried out in this chapter. The 
xenograft work is based on one model at one dose level, which may not be 
reflective of the clinical setting. Certainly the work focused on the immune 
system is undermined by the use of SCID mice, which are severely immune-
compromised. Moreover, by the time tumours demonstrated a resistance 
phenotype, all vehicle-treated tumours had been sacrificed leaving us without 
any time-matched controls. Gene expression analysis in the host compartment 
was complicated by the fact that sunitinib significantly decreased the number of 
host cells at the tumour site. Although we could allow for the general decrease 
in host cells using a mouse specific 18s probe we could not account for sunitinib 
changing the composition of the remaining host cells. It is possible that some of 
the gene expression changes we saw in the host compartment merely reflect a 
change in the composition of remaining host cells.  
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In summary, the gene expression analysis showed that several different pro-
angiogenic and pro-metastatic pathways were activated by the time tumours 
were rebounding. Some of these genes seemed to be up-regulated to 
compensate for the hypoxic microenvironment caused by sunitinib therapy. 
Other genes such as S100A4 and PGF, although up-regulated at the time of 
resistance, and potentially contributing to that process, appeared to be up-
regulated due to the natural course of disease, rather than as a response to 
therapy. Due to the prior selection of genes thought to potentially play a role in 
tumourgenesis, most of the genes and pathways implicated in this study have 
been previously implicated in the resistance process. Despite this, gene pathway 
analysis suggested a wound healing or ‘fibrosis-like’ process was taking place 
and this lead to the novel finding that VEGFr TKIs increase collagen deposition in 
both xenograft and RCC patient tissue. To our knowledge, collagen deposition 
has not previously been described as a potential resistance mechanism to anti-
VEGFr therapy. Due the potential for collagen to affect both angiogen 
 esis and metastasis further investigation of this novel finding is 
warranted. 
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Chapter 6: 
Summary and Future Work 
 
 
VEGFr-TKIs are established as first line therapy for metastatic RCC 128, 129. A 
minority of tumours are inherently resistant to therapy while a larger proportion 
are initially sensitive and subsequently acquire a resistant phenotype 75. There 
are currently no clinically validated biomarkers that predict VEGFr TKI treatment 
response or the onset of acquired resistance 130. Moreover, when resistance 
occurs, current second line treatment offers only a modest improvement in 
patient survival 131.   
 
For patients presenting with metastatic disease current standard of care is for 
nephrectomy which takes place prior to treatment onset. Prior nephrectomy 
together with the difficulty in accessing metastatic tissue has meant that most 
biomarker studies to data have focused on tumour samples taken prior to 
therapy despite preclinical data that suggests treatment induces dynamic 
changes in tumour biology 37, 132. We hypothesise that it is important to 
understand these dynamic changes in order to understand the mechanisms that 
mediate acquired resistance, and make informed choices about how to treat 
patients that become resistant to these agents. 
 
This majority of work contained in this thesis is aimed at improving our 
understanding of the molecular drivers of acquired resistance. To this end a 
preclinical model of resistance was used together with tissue taken from RCC 
patients prior to planned nephrectomy and after 12-16 weeks of TKI therapy. In 
both preclinical and clinical tissue, a wide range of molecular changes were 
observed: 
 
Treatment resulted in the up-regulation of multiple pro-angiogenic factors. FGF-
2 and HGF-MET receptor have long been thought to provide alternative 
pathways by which tumours can escape VEGF-targeted therapy. Both pathways 
were seen to be up-regulated in clinical samples; cytoplasmic FGF-2 and MET 
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receptor on tumour vessels were significantly increased. In our preclinical 
model, FGF-2 ligand and MET receptor were both increased in non-malignant 
cells residing in the tumour microenvironment. No increase was in tumour cells. 
In addition, VEGF and PGF were seen to be up-regulated in our preclinical model 
in both the tumour and hose compartments (technical problems with the IHC 
prevented their measurement in clinical samples). Our preclinical model 
suggested that the highest up-regulation of VEGF ligand and MET receptor 
coincided with the maximum reduction in vessels density, potentially indicating a 
compensatory mechanism. Interestingly, PGF increased with time even in 
vehicle treated tumours. Moreover, PGF was up-regulated to the greatest degree 
at the last time-point, not at the point of maximum vessel reduction (a similar 
expression profile was observed for s100a4, a gene implicated in promoting 
renal cancer metastasis).  
 
This raises an interesting hypothesis, the dynamic molecular changes that lead 
to acquired resistance observed in the clinic may occur through two distinct 
processes: 
 
 the tumour may up-regulate pathways to compensate for hypoxia 
caused by VEGFr-TKI treatment 
 the natural course of disease is associated with changes in gene 
expression over time and some of these genes up-regulated later 
timepoints may contribute to a resistant phenotype  
A major limitation of our analysis of clinical tissue is that time-matched controls 
were not possible. As a result, we cannot discount the possibility that the natural 
course of disease is contributing to the observed molecular changes in 
sequential patient tissue. 
 
In addition to the multiple pro-angiogenic factors up-regulated by treatment, 
several genes associated with metastasis were affected in the preclinical model. 
Metastasis is thought to be play an important role in VEGFr-TKI resistance. A 
major limitation of our preclinical work was our sole focus on the primary 
tumour site. 786-O xenografts do not easily metastasise beyond the primary 
tumour when cells are inoculated sub-cutaneously. Moreover, tumours were 
measured with callipers rather than using imaging equipment so any metastasis 
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would not have been observed. Consequently, although it can be verified that 
VEGFr-TKI treatment affected genes associated with metastasis, there is no 
evidence that this translated into the generation of metastatic tumours. 
 
Ki67 analysis of clinical tissue showed an increase in the proliferation index of 
treated tumours, however this did not reach statistical significance in matched 
samples and tumour Ki67 was not significantly affected in our preclinical model. 
Nevertheless the observed increase in Ki67 in clinical samples suggests further 
investigation of this potential resistance mechanism is warranted.  
 
In summary, several different pathways were affected by VEGFr-TKI therapy 
and many of these genes have been previously implicated as drivers of 
resistance. Because of the unique nature of the clinical tissue samples, this is (to 
our knowledge) the first time that these resistance mechanisms have been 
validated in clinical tissue. Two important conclusions could be drawn from this 
headline result. Firstly, the results question the use of tissue taken prior to 
treatment onset to select patients likely to benefit from VEGFr-TKI treatment 
disease. Secondly, the addition of therapy targeting any one of the many 
resistance pathways implicated, for example the FGF-2 or MET receptor 
inhibitors, may have an incremental on treatment efficacy. However, the 
number of different pro-angiogenic and pro-metastatic pathways affected by 
VEGFR-TKI treatment, and potentially contributing to acquired resistance, 
suggests that targeting any one of these individual pathways in isolation may 
not to lead to a long-lasting improvement in treatment response. In line with 
hypothesis dovitinib, a dual VEGFr-FGFr TKI, failed to show a significant 
improvement over sorafenib in patients that had previously progressed on 
VEGFr-TKI therapy 133. 
 
A key motivation of developing a preclinical model of resistance was the ability 
to test treatment combinations that may delay or prevent resistance occurring. 
Before conducting the in depth resistance analysis described above, we 
hypothesised that SRC inhibitors may provide a rationale combination with 
VEGFr-TKIs to delay or prevent acquired resistance. This hypothesis was based 
on work by other groups that the SRC pathway can affect the two key 
mechanisms of resistance, namely metastasis and (renewed) angiogenesis. The 
data shows that combining the SRC inhibitor with VEGFr-TKI therapy had an 
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additive anti-tumour effect in our preclinical model of resistance, when 
compared to VEGFr-TKI monotherapy. However, gene analysis suggested that 
the addition of the SRC inhibitor had no significant effect on any of the 
molecular pathways associated with VEGFr-TKI resistance described above. A 
major limitation of the work investigating the potentially utility of SRC inhibition 
was the failure to identify a molecular mechanism by which the SRC inhibitor 
was providing this additive anti-tumour effect. Future work in clinical samples 
taken from patients treated with the VEGFr-TKI SRC inhibitor combination may 
provide insight here. In particular, we hypothesise from the preclinical data that 
VHL status and phospho-STAT3 activity may influence efficacy. Future 
translational efforts in clinical samples will prioritize these two biomarkers.  
 
Additional work is ongoing using the sequential tissue taken from VEGFr-TKI 
treated patients. Some of this work may overcome some of the limitations with 
the work contained in the thesis. Perhaps the most important future work will 
expand the investigation into the effect of VEGFr-TKI on the immune system of 
patients. The ultimate goal of any translational research should be aimed at 
improving patient outcome through increased and sustained response to 
treatment. Of all the current drug candidates currently in clinical trials for RCC 
patients, immunotherapeutic approaches arguably hold the most promise. Unlike 
VEGFr-TKI treatment, where acquired resistance inevitably leads to tumour 
progression, immunotherapy has been associated with sustained treatment 
responses, and in some cases, remission. Consequently, the addition of an 
effective immunotherapy agent to VEGFr-TKI therapy holds promise. However, 
the effects of VEGFr-TKI therapy on immune compartment may complicate 
matters. Moreover, the preliminary work contained in this thesis suggests that 
different TKIs may have substantially different effects on CD3+ T cells the key 
effector cell of some of the most promising immunotherapies in clinic trials. 
Further work is needed to understand the effects on T cells and other key 
effector cells. IHC reagents are available to identify subpopulations of T cells. In 
addition to investigating the effects on CD4+ and CD8+ cells, it would be 
insightful to understand the effects on markers of immune-suppression. An 
increasing body of evidence suggests that PD-1 and CTLA4 expression play an 
important role in tumourgenesis. In addition it would be interesting to 
investigate expression of LAG-3 and TIM-3, which are known to be transiently 
expressed on CD8+ and CD4+ T cells respectively 134.  
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In addition, it would be insightful to understand the effect on other cell types 
important to mounting an immune reaction. In particular, NK cells should also 
be prioritized in part due to their ability to induce antibody-dependent cell-
mediated cytotoxicity (ADCC). ADCC has been shown to be an important 
mechanism of action for antibody therapy. Any effect the different VEGFr-TKIs 
have on NK cell number and activation could be an important factor for 
immunotherapies currently in clinic, particularly immunotherapies that are 
thought to benefit from ADCC.  
 
There are several limitations to the work described in this thesis. For the most 
part, the preclinical work was limited to one xenograft model (786-O cell line) in 
a SCID mouse. Extending the work to further xenograft models and taking 
tissue at further timepoints may help elucidate which genes are the key drivers 
of the resistance process. Unfortunately there are no clear cell renal carcinoma 
models that grow in immuno-competent mice, which limits the value of any 
further preclinical investigation of the effect of VEGFr-TKIs on immune response. 
Consequently, patient tissue is likely to be more insightful when examining the 
effect of VEGFr-TKI on the immune compartment. 
 
Antibody-drug conjugates (ADCs) are empowered antibodies that harness the 
specificity of antibody therapies with the cell killing effects of chemotherapy. 
This class of drug have demonstrated efficacy in other tumour types, particularly 
breast cancer, and may prove to be effective in the RCC setting, despite the 
previous failures of traditional chemotherapies. An important hypothesis to 
emerge from this work is that derives from the Ki67 IHC work in sequential 
tissue. Our data, although not conclusive, suggests that VEGFr-TKI may lead to 
a more aggressive, proliferative phenotype. A proliferative phenotype may help 
sensitize cells to ADCs, particularly those drugs using cell-cycle dependent 
tubulin polymerisation inhibitors. Further investigation of the effect of VEGFr-
TKIs of tumour cell proliferation may provide important insight into the use of 
ADCs in combination with, or subsequent to, VEGFr-TKI therapy. 
 
Gene expression analysis of the xenograft tumours lead us to hypothesise that 
VEGFr-TKI treatment was leading to a process resembling fibrosis or wound 
healing. Since fibrosis is characterised by increased collagen deposition, collagen 
volume in the xenograft tumours was investigated. VEGFr TKIs resulted in a 
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significant increase in collagen deposition and this result was validated in clinical 
samples. To our knowledge, this has not been noted in either preclinical models 
or clinical tissue. Since collagen is thought to promote pathological angiogenesis 
123 124 125 and metastasis 126 it is conceivable that increased collagen deposition 
represents a novel mechanism of resistance that contributes to tumour 
progression. However, a number limitations to our work prevents us from 
drawing such a conclusion at this stage.  
 
As yet, the type of collagen deposited in the preclinical or clinical tissue has not 
been characterized. Different collagens are thought to have different effects on 
angiogenesis and cell signaling within the tumour compartment. Collagen has 
been shown to have pro- and anti-tumour effects within the same tumour type 
135, 136, while it’s impact in our work has not been established. It may be possible 
to address this in our preclinical model with the use of an anti-fibrotic agent, 
reducing collagen deposition. Any such efforts may be complicated by the fact 
that many drugs used to reduce fibrosis also have direct effects on vessels and 
blood flow 137, 138. Intriguingly, retrospective analysis suggests that patients 
presenting on anti-fibrotic agents had significantly higher progression free 
survival 139. Further work is warranted to better understand whether increased 
collagen deposition contributes to VEGFr TKI resistance and whether the use of 
anti-fibrotic agents can help slow tumour progression. 
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Example of Patient Information and Patient Consent Form for tissue analysed in 
this thesis. 
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PATIENT INFORMATION SHEET 
 
A PHASE II STUDY INVESTIGATING UPFRONT PAZOPANIB IN METASTATIC 
CLEAR CELL RENAL CANCER  
(PANTHER) 
VERSION  5.0 DATED  21ST DECEMBER 2011 
 
1. Invitation paragraph 
 
You are being invited to take part in a research study. Before you decide whether or not you 
want to take part, it is important for you to understand why the research is being done and 
what will be involved.  
 
Please take time to read the following information carefully. Talk to others about the study if 
you wish. Ask your doctor if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
 
2. What is the standard treatment for metastatic kidney cancer? 
 
When kidney cancer spreads beyond the kidney it is known as metastatic kidney cancer, 
which is difficult to treat.  
 
A new type of oral drug known as pazopanib, which stops the growth of cancer cells, has 
updated previous treatments. 
  
At the moment, most patients with metastatic kidney cancer have surgery to remove the 
kidney before starting oral drug treatment. This surgery is called a nephrectomy. It is 
unknown whether this surgery is of any benefit in the long term, as it delays starting the drug 
therapy to treat cancer which has spread to other sites of the body.  
 
So far previous research studies have looked at giving a period of another drug, sunitinib, 
followed by surgery. These studies are designed to hopefully make the tumour smaller, 
therefore making surgery easier. Published results with this approach are promising. So far 
there are no research studies in this area with pazopanib. 
 
 
 
3. What is the purpose of this study? 
 
The purpose of this study is to look at the effect of giving pazopanib for 14 weeks before 
surgery in metastatic kidney cancer. The drug treatment is designed to target all the cancer 
cells, in the kidney and other places, unlike surgery which will only treat the cancer in the 
kidney.  
 
The drug used in this study is pazopanib. It is a tablet that is taken by mouth. The tablet 
works by stopping cancer cells from growing. It also works in kidney cancer by reducing the 
blood supply to cancer cells. 
 
It is planned that approximately 95 evaluable patients across twelve UK centres, will be 
recruited onto this study over a 20 month period. 
 
 
4. Why have I been invited to take part? 
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You have been invited to take part in this study because your scan suggests that you have 
kidney cancer which has spread to organs beyond the kidney. Your doctor feels that you 
may benefit from receiving pazopanib therapy.  Your doctor may have discussed the 
possibility of surgery with you. The key to this study is to determine if 14 weeks of pazopanib 
prior to surgery is of benefit. 
 
 
5. Do I have to take part? 
 
No. It is up to you to decide whether or not you wish to take part. If you choose to take part 
you will be asked to sign the consent form. You will receive a copy of this information sheet 
and your signed consent form to take away.  
 
If you do decide to take part you are free to withdraw from the study at any time and without 
giving a reason. A decision to withdraw or not to take part, will not affect the standard of care 
you receive. However, you will not be able to restart pazopanib as part of the study. You will 
be able to go on and receive a different agent if pazopanib fails. Your treatment will be 
decided by your treating doctor. 
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Section A: Main Compulsory Components of Study 
 
1. What will happen to me if I take part?       
 
Once you have decided to take part in the study and signed a consent form, your doctor will 
make sure that you are suitable for entry onto the study. The following tests may need to be 
carried out before you can start study treatment: 
 
 full medical history (including information about other medications and illnesses)  
 clinical examination 
 blood tests 
 pregnancy test  
 Computerised Tomography (CT scan) of the chest abdomen and pelvis within 3 
weeks of starting the study if this has not already taken place.  
 
In order to confirm your diagnosis of kidney cancer, a tissue sample of the cancer in your 
kidney will need to be taken; this is known as a biopsy. This will take place whether or not 
you go into the study. For the biopsy you will need to have a local anaesthetic before a 
needle is passed into the kidney to remove some tissue. This tissue will be looked at further 
to see if there are cancer cells.   
 
Once your study doctor is satisfied that you meet all the requirements you will then be asked 
to sign a consent form before you begin the study. The study drug will be prescribed for you 
to take orally, two tablets once a day. You will be asked to continue taking the drug without 
any breaks until your surgery.  
 
You will be seen in clinic after the first 4 weeks of starting the drug to make sure you are not 
experiencing any side effects.  
 
Day-to-day effects which may occur when taking pazopanib include a loss of appetite and 
nausea,  changes in hair and skin colour, hair loss, rash, tiredness, bleeding (in the lungs, 
urine, nose and intestines), numbness in the hands and feet and an increase in blood 
pressure. The drug can also reduce your blood sugar levels, white blood cells, lipids and 
platelets in the blood and cause a change in the function of the liver.  Other effects include a 
decrease in thyroid activity, weight loss, headache, change in taste, stroke, heart 
abnormalities, chest pain, abnormal amount of protein in the urine and loose stools 
(diarrhoea). 
 
Appointments will then take place at 8 weeks and 12 weeks. During these visits you will 
have blood tests (approximately 2 teaspoons of blood will be taken), assessment of any side 
effects and a full physical examination if necessary. You will be allocated a research nurse 
who you can contact by telephone if any problems occur in between these visits.  
 
A CT scan will take place at 6 weeks to make sure the cancer is not growing. This involves 
lying on a table for 5 minutes inside a machine that looks a bit like a hollow cylinder. Some 
dye (called contrast) will be injected into your vein and pictures will be taken of the tumour 
inside of your body. 
 
You will receive between a minimum of 12 to a maximum of 16 weeks of pazopanib 
treatment. After this, you will have another CT scan to see whether the cancer has shrunk in 
size. At this point your doctors will discuss surgery with you (please see Figure 1).  
Before surgery you may be required to see the surgical team and have an ultrasound scan 
of the heart and an ECG (electrocardiogram) to make sure you are well enough to have the 
surgery. An ultrasound scan of the heart checks to see if there are any cardiac problems. An 
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Yes 
No 
ultrasound is a harmless procedure in which your doctor will place some lubricating gel on 
the surface of your chest. A hand-held device which is similar to a blunt pen, will then be run 
over this area and pictures will be taken. An ECG is used to look at the electrical activity of 
the heart which can help rule out any abnormal heart rhythms. When having an ECG you will 
have 10 small sticky patches placed over your chest, arms and legs. These will be linked to 
the machine that will record the electrical activity of the heart.  
 
You will be asked to stop taking pazopanib for at least 48 hours before the surgery and will 
restart taking pazopanib at least 2 weeks after surgery. A CT scan will be repeated 6 weeks 
after restarting pazopanib to make sure the treatment is still working. The pazopanib 
treatment will continue as long as the cancer appears to be responding, unless you develop 
severe side effects or if you wish to stop.  
 
You may also be asked to have an MRI scan (magnetic resonance imaging) to help any 
biopsy procedure/ surgery. Your doctor will discuss further details about this type of scan 
should you require one.  
 
If you are not able to have surgery (due to you not being well enough), you can continue on 
pazopanib therapy for as long as your doctor feels that it is of benefit to you. However, you 
may be asked to have a repeat biopsy at the time that the surgery would have taken place. 
The pazopanib treatment will continue as mentioned above, until there is evidence that it is 
no longer stopping the disease.  
 
During the study you will be reviewed for side effects. If these occur, and are serious your 
doctors may advise a break in treatment until the side effects stop. Your doctor may also 
arrange to reduce the amount of pazopanib taken or even stop the treatment completely. 
 
 
 
                        
 
 
 
 
         
                    
  
 
Figure 1. 
 
 
 
2. What will happen to any samples I give? 
 
A sample will be taken from your kidney, which is less than 1 gram, (approximately the 
weight of a paperclip) before starting treatment and will be used to confirm the type of cancer 
cells you have. This biopsy is part of standard treatment and you will still undergo this even if 
you do not take part in this research study. A sample of the affected kidney will also be 
removed during surgery (or for those patients not having surgery, during the repeat biopsy). 
We will compare the two tissue samples. This will allow us to find some areas in the tissue 
that may be reacting to treatment. Therefore it may be possible to use this information to 
predict future patients who will have a greater reaction to treatment. This will also allow us to 
gather new information to help patients in the future. 
With your permission, any tissue remaining as a result of this project will be stored safely in 
a licensed tissue bank to be used for future research purposes. This could also include any 
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blood samples that may be taken if you go on to the main study. The tissue may be stored 
and used by Barts and the London NHS School of Medicine and Dentistry, and for approved 
research within a hospital, university, non-profit institution or a company laboratory 
within/outside the EU. Samples will be lawfully disposed of, when necessary. If you are 
willing for your tissue to be stored for future research you will be asked to sign a separate 
consent form. 
 
 
3. What are the alternative treatments available? 
 
Your doctor will discuss with you the alternative treatments that are available to help to 
manage your condition. These alternative treatments include sunitinib or immune therapy, 
which is widely available within the UK. Your treatment may also include surgery. 
 
It is your decision about which treatment you wish to have and some people with this 
condition choose to have no further drug treatment. If you choose not to participate, your 
treating doctor will tell you more about all your options.   
 
 
4. What are the side effects of the study drug, pazopanib? 
 
Side effects that patients in other studies have experienced when taking pazopanib and the 
frequency of their occurrence include 
 
Very common: (more than or equal to 1 in 10) 
 
Common: (more than or equal to 1 in 100 and less than 1 in 10) 
 
Uncommon (more than or equal to 1 in 1000 and less than 1 in 100)                                                                
 
Adverse Reaction Frequency 
Fatigue, weakness Very common 
Headache Very common 
Weight loss Very common 
Hair discolouration Very common 
Increased blood pressure Very common 
Diarrhoea, Nausea, Vomiting, abdominal pain Very common 
Decreased platelets, and white blood cells Common 
Reduced thyroid function Common 
Change in taste Common 
Heart abnormalities (QT prolongation, 
transient ischaemic attack, myocardial 
ischaemia) 
Common 
Nose bleeds, blood in urine Common 
Indigestion Common 
Liver function changes Common 
Rash, hair loss, Skin discolouration Common
Abnormal amount of protein in the urine Common
Chest Pain Common 
Decreased blood sugar levels Uncommon 
Stomach disorders Uncommon 
Bleeding in the lungs, intestines and brain Uncommon 
Stroke Uncommon 
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Not all side effects of pazopanib are known or predicted. Many side effects go away when 
the study drug is stopped, but in some cases, it is possible that the side effects could be 
serious, long lasting, permanent (stroke, change in thyroid function skin and hair changes) or 
fatal (stroke, liver dysfunction and gastrointestinal perforation).  You should discuss these 
with your doctor.  In addition, there may be side effects that we cannot predict. 
 
If during the course of this trial any new findings about pazopanib become available which 
may influence your decision to continue participating in this study, your study doctor will 
inform you. 
 
If you do experience any unpleasant side effects or discomfort during the study you should 
inform your study doctor either at the next visit or sooner if you wish, by using the telephone 
contact number in this patient information sheet. 
 
Pazopanib can potentially interact or interfere with a number of other drugs. For these 
reasons you should discuss all the drugs you take regularly or intermittently with your cancer 
doctor. The drugs which could be affected include specific antidepressants, erectile 
dysfunction drugs, specific lipid lowering drugs anticoagulants, oral diabetic drugs, specific 
sleeping pills, specific antihypertensives, steroids, specific antibiotics and oral 
contraceptives. If you are on one or more of these drugs, we may need to monitor you or 
change your drug before starting therapy. Your current medication should be discussed with 
your treating doctor. 
 
 
5. What are the possible disadvantages and risks of taking part? 
 
One of the risks of taking pazopanib is that it may not work for you.   
 
Also we do not yet know if surgery after 14 weeks of pazopanib is the ideal time to perform 
the surgery. Additionally it is not yet known if this surgery is more difficult or easier after 
taking pazopanib.  
 
 
WOMEN 
There could be risks to an unborn child in this study, therefore, If you are pregnant you 
cannot enter the study. If you become pregnant during the study, these risks could affect you 
or your unborn child.  You must agree to use adequate birth control during the study, which 
you can discuss with your study doctor. You must continue using birth control for at least 28 
days after you stop taking pazopanib.   
 
Before the study, a pregnancy test will be done for all women who are able to get pregnant. 
The test might not be enough to detect an early pregnancy so tests may be repeated during 
the study. If you think you may be pregnant, you must tell your study doctor immediately. 
Pregnancy will be a reason to stop study treatment.  If you become pregnant, information on 
the outcome of your pregnancy will be requested. 
 
MEN 
If your spouse or partner thinks they are pregnant during the study, tell your study doctor 
immediately.  The effect of pazopanib on sperm is not known, so you must agree to use 
adequate birth control during the study, which you can discuss with your study doctor. You 
must continue using birth control for at least 28 days after you discontinue the study. 
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6. What are the possible benefits of taking part? 
 
The medicine and surgery you receive may help you and your disease.  You may not 
personally benefit from being in this study.  However the information we gain from this study 
might help us to treat future patients who have metastatic kidney cancer. 
 
 
7. What will happen if I don’t want to carry on with the study? 
 
You can choose to withdraw from the study at any time. Any information that has already 
been collected will be processed as part of the study, but no further information will be 
collected.  A decision to withdraw at any time, or a decision not to take part, will not affect 
the care you receive. If you do decide to stop your treatment you will not be able to go back 
onto the study.    
 
 
8. What if relevant new information becomes available?   
 
Sometimes during the course of a research study, new information may become available 
about the drug that is being studied.  If this happens, your study doctor will tell you about it 
and discuss with you whether you want to continue in the study.  If you decide to withdraw, 
your study doctor will make arrangements for your care to continue.  If you decide to 
continue in the study you will be asked to sign an updated consent form to reflect any 
changes as a result of the new information. 
 
Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He/she will explain the reasons and arrange for 
your care to continue. 
 
 
9. What happens when the research study stops? 
 
If the research study stops, you will be informed and will be offered alternative treatment. 
 
 
10. What if there is a problem with the study? 
 
We would not expect you to suffer any harm or injury because of your participation in this 
study.  If you are harmed by taking part in this study, there is no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have grounds 
for legal action but you may have to pay your legal costs. Regardless of this, if you wish to 
complain or have any concerns about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms should be available to you. Participants with Personal Medical Insurance are 
advised to contact their companies and inform them that they intend to take part in the trial.   
 
 
11.  How do I make a complaint? 
 
Please contact Patient Advisory Liaison Service (PALS) if you have any concerns regarding 
the care you have received, or as an initial point of contact if you have a complaint.  Please 
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telephone ~insert number~, minicom ~insert number~, or email ~insert email address~ you 
can also visit PALS by asking at any hospital reception. 
 
 
 
 
12. Will my taking part in the study be kept confidential?  
 
Yes. All information which is collected about you during the course of the research will be 
kept strictly confidential.  If you consent to take part in the research the people conducting 
the study will abide by the Data Protection Act 1988, and the rights you have under this Act.   
 
If you wish to take part in this study we will ask your permission to contact your GP to let 
them know of your potential participation in the study. This is done so that all the doctors 
involved in your care are aware of the medicines you are taking.  They can also tell us if 
there are any medical reasons why you should not take part in the study.  Your hospital 
notes will also state that you are in the study and a label will be clearly visible on front cover 
of notes.  
 
If you join the study, some parts of your medical records and the data collected for the study 
will be looked at by authorised personnel from your treating centre and authorised personnel 
from Bart’s & The London NHS Trust, GlaxoSmithKline and Queen Mary University of 
London who are the sponsor of this study. It may also be looked at by representatives of 
regulatory authorities and other authorised personnel from your trust, to check that the study 
is being carried out correctly. All will have a duty of confidentiality to you as a research 
participant and nothing that could reveal your identity will be disclosed outside the research 
site. All data will be stored in a locked and dedicated room at the Centre for Experimental 
Cancer Medicine, which will only be accessible by authorised personnel. 
 
 
13. What will happen to the results of the research study? 
 
The researchers hope to publish the results of this study in a medical journal.  This usually 
takes place months after the study has been completed.  You or your relatives will be offered 
a summary of the study results.  It will not be possible to identify you in the report/publication.  
 
 
14. Who is organising and funding the research?   
 
This is an investigator-initiated study.  Dr Thomas Powles of St. Bartholomew’s Hospital is 
the Chief Investigator. Queen Mary University of London is sponsoring the study.  The 
doctors and other members of the clinical research teams are not being paid for participating 
in this study. GlaxoSmithKline is providing financial support for this study and will be 
providing the pazopanib for use in the study free of charge. Patients who wish to participate 
in the study will have their extra travel costs, (which are any additional travel costs to 
standard healthcare) reimbursed. 
 
 
15. Who has reviewed the study?  
 
This study has been through a peer review process and was given approval by Bart’s & The 
London NHS Trust Cancer Clinical Academic Unit Review Committee. A peer review 
involves the examination of an author’s work by other experts in the same field. These 
referees each return an evaluation of the work which may include suggestions of 
improvements if necessary. 
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Your local NHS trust has been given approval for the study to take place at your hospital. 
The study has also been given a favourable ethical opinion for conduct by the South East 
Research Ethics Committee. This Committee assesses the study and decides if the study 
will be in the best interests for the patients involved. 
 
 
16. Contact Details 
 
You can contact your local Principal Investigator or Research Nurse to discuss your 
concerns and/or to get help. 
  
Name:   
Address: ~insert details~ 
 
Tel:     
Fax:   
 
Out of hours: Please contact ~insert details~ and ask to speak to ~insert details~ . 
 
 
 
 
If you wish to take part in the main section (A) of the Study, then Consent Form A will have o 
be signed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ to be printed on headed paper ~ 
PANTHER Consent form A Version 1 dated 16th November 2009  Page 1 
 
CENTRE NUMBER:  
STUDY NUMBER:  RC-2009-02 
PATIENT INITIALS: 
DATE OF BIRTH: 
 
PATIENT CONSENT FORM A: Main Compulsory Components of Study 
 
 
STUDY TITLE: A PHASE II  STUDY INVESTIGATING UPFRONT PAZOPANIB IN 
METASTATIC CLEAR CELL RENAL CANCER (PANTHER).   
VERSION 1  [DATED 16TH NOVEMBER 2009] 
 
 
Name of Researcher:  ……………………………………………………………… 
 
                     Please initial box 
1. I confirm that I have read and understand the information sheet dated: ~insert correct 
version number~ for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
 
3. I understand that relevant sections of any of my medical notes and data collected 
during the study, may be looked at by responsible individuals from regulatory authorities 
or from Barts and the London/ Queen Mary University of London, where it is relevant to 
my taking part in this research.  I give permission for these individuals to have access to 
my records.  
 
 
4. I agree to my GP being informed of my participation in the study. 
  
5. I understand that samples of my tissue will be taken from me during the study. I agree 
for my tissue to be used in this research project. 
 
 
6. 
 
I agree to take part in section A, the main components of the study. This potentially 
includes freezing and storage of tissue for future research 
 
 
 
                                                                
___________________________ ___________________ _____________________ 
Name of Patient Date Signature 
 
 
___________________________ ___________________ _____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
___________________________ ___________________ _____________________ 
Researcher Date  Signature 
 
1 for patient; 1 for researcher; 1 original to be kept with hospital notes 
                             
1 copy for Patient, 1 copy for Investigator, 1 copy in the hospital notes 
Version 2, 2nd March 2009 
 
CONSENT TO COLLECT GENITO-URINARY TISSUE AND BLOOD 
SAMPLES FOR RESEARCH 
Patient’s full name 
 
 
Investigator: 
Dr D Berney  
Dr T Powles, Dr J Shamash 
 
Date of Birth 
 
Ethic Committee Ref: REC 09/H0704/4 
Description of tissue: 
: 
Hospital name and number 
 
 Blood collection: 
Yes/No 
 Patient 
initials  
I understand that tissue will be taken during my treatment/investigation and 
will not be used for diagnostic purposes. I agree that this tissue will be 
stored (-80C freezer and Liquid Nitrogen) in the Orchid Tissue Bank for 
current and future research. 
 
I accept that I have given my consent voluntarily to the storage of this 
additional tissue and that I am free to withdraw my consent at any time and 
the tissue will then be destroyed. 
 
I agree that the tissue may be used for future genetic research. It may not be 
used for research in reproductive cloning. The sample will not be tested for 
inherited diseases without my consent. 
 
I agree that my health records may be used by authorised members of staff 
who are not directly involved in my clinical care and my hospital number is 
written above. 
 
If blood collected: 
 
I understand, the blood collected will not be taken for diagnostic purposes 
 
I am free to withdraw my consent at any time and the blood will then be 
discarded. 
 
I agree that the blood may be used for future genetic research. Blood cells 
will not be used for reproductive cloning and inherited disease research. 
 
 
_________________________ ___________  ___________________ 
Name of Patient   Date   Signature 
 
 
_________________________ ___________  ___________________ 
Name of person taking consent Date   Signature 
 
                             
1 copy for Patient, 1 copy for Investigator, 1 copy in the hospital notes 
Version 2, 2nd March 2009 
 
GENITO-URINARY TISSUE AND BLOOD SAMPLES COLLECTION 
DETAILS OF RESEARCH: 
 
 
The tissue samples taken routinely during your procedure are sent to the hospital 
laboratory. This is routine practice, essential for diagnosis and for planning further 
treatment. By giving your consent at the same time, excess tissue not required for 
diagnosis will be collected by the Orchid Tissue Bank and stored in -80C freezer 
and/or Liquid Nitrogen, and used for current and future research.  
 We are mainly collecting tissue from the bladder, prostate, testis, kidney or 
penis, or the peripheral blood. The most important areas of research will be to improve 
the methods of diagnosis and identification of the causes of cancer. This primarily 
involves the study of tumour markers in blood and tissue to detect and analyse proteins 
that are differently expressed in tumours than in normal tissue. We are also studying 
genes (specific sequences of DNA) and chromosomal damage that develop during 
tumour progression.  
All staff undertaking future studies will abide by the Data Protection Act 1998, 
with any medical information relating to you being kept confidential. The tissue may 
be given to external organisations for approved research but tissue will not be sold, 
although costs will be recovered without any financial benefit to either you or the 
researcher. All tissue will be disposed of lawfully when it is no longer required. 
The information obtained from our research may be published in scientific journals 
and discussed at scientific and medical conferences. However, all the documents 
relating to you will be completely anonymous.  
 
If a blood sample is being requested, this will purely be for specific research 
projects and not for diagnostic purposes. The blood will not be sold and it will be 
disposed when it is no longer required. 
 
IMPORTANT INFORMATION 
¾ Your treatment will not be affected if you decline to participate. 
¾ The work will have no direct implications for your personal health, due to the 
type of research involved.  
¾ Samples may contain personal information but all such information will be 
anonymised when the results are published or when samples are given to 
external organisations.  
¾ You can withdraw your consent at any time. Please send us a letter containing 
your contact details. In return, you will be informed, by courier that your 
tissue has been destroyed and removed from the tissue bank. 
 
For more information: 
Dr D Berney 
ORCHID TISSUE BANK 
Molecular Oncology & Imaging, Institute of Cancer, 
Barts and The London Queen Mary's School of Medicine and Dentistry 
John Vane Science Centre, Charterhouse Square 
London EC1M 6BQ
 
Thank you for your help. 
